Patent Grant
9309250
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 15, 2012, is named 11-126US_Seq.txt and is 1 kilobyte in size.
ATR (“ATM and Rad3 related”) kinase is a protein kinase involved in cellular responses to DNA damage. ATR kinase acts with ATM (“ataxia telangiectasia mutated”) kinase and many other proteins to regulate a cell's response to DNA damage, commonly referred to as the DNA Damage Response (“DDR”). The DDR stimulates DNA repair, promotes survival and stalls cell cycle progression by activating cell cycle checkpoints, which provide time for repair. Without the DDR, cells are much more sensitive to DNA damage and readily die from DNA lesions induced by endogenous cellular processes such as DNA replication or exogenous DNA damaging agents commonly used in cancer therapy.
Healthy cells can rely on a host of different proteins for DNA repair including the DDR kinase ATR. In some cases these proteins can compensate for one another by activating functionally redundant DNA repair processes. On the contrary, many cancer cells harbour defects in some of their DNA repair processes, such as ATM signaling, and therefore display a greater reliance on their remaining intact DNA repair proteins which include ATR.
In addition, many cancer cells express activated oncogenes or lack key tumour suppressors, and this can make these cancer cells prone to dysregulated phases of DNA replication which in turn cause DNA damage. ATR has been implicated as a critical component of the DDR in response to disrupted DNA replication. As a result, these cancer cells are more dependent on ATR activity for survival than healthy cells. Accordingly, ATR inhibitors may be useful for cancer treatment, either used alone or in combination with DNA damaging agents, because they shut down a DNA repair mechanism that is more important for cellular survival in many cancer cells than in healthy normal cells.
In fact, disruption of ATR function (e.g. by gene deletion) has been shown to promote cancer cell death both in the absence and presence of DNA damaging agents. This suggests that ATR inhibitors may be effective both as single agents and as potent sensitizers to radiotherapy or genotoxic chemotherapy.
ATR peptide can be expressed and isolated using a variety of methods known in the literature (see e.g., Ünsal-Kaçmaz et al, PNAS 99: 10, pp 6673-6678, May 14, 2002; see also Kumagai et al. Cell 124, pp 943-955, Mar. 10, 2006; Unsal-Kacmaz et al. Molecular and Cellular Biology, February 2004, p 1292-1300; and Hall-Jackson et al. Oncogene 1999, 18, 6707-6713).
For all of these reasons, there is a need for the development of potent and selective ATR inhibitors for the treatment of cancer, either as single agents or as combination therapies with radiotherapy or genotoxic chemotherapy.
The present invention relates to pyrrolopyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. These compounds have an unexpected ability to treat cancer as single agents. These compounds also show surprising synergy with other cancer agents, such as cisplatin, in combination therapies.
One aspect of this invention provides a compound of Formula I:
or a pharmaceutically acceptable salt thereof wherein:
In some embodiments, J is halo, ═O, CN, V1, (V)t—R2, or
In some embodiments, R3 is H, halo, CN, or C1-3alkyl wherein up to one methylene unit of said C1-3alkyl is optionally replaced with O, NH, or S; and wherein said C1-3alkyl is optionally and independently substituted with 1-3 occurrences of halo or OH;
One aspect of this invention provides compounds wherein Q is a 6-membered aromatic or nonaromatic ring having 0-1 nitrogen atoms. In some embodiments, Q is phenyl, pyridyl, or a pyridinone ring. In other embodiments, Q is phenyl.
In certain embodiments, Q is substituted in the para position with J. In some embodiments, J is V1 or (V)t—R2. In other embodiments, V1 and V are each independently CO or SO2. In yet other embodiments, V1 and V are SO2. In some embodiments, R2 is a 3-7 membered heterocyclyl ring having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. In other embodiments J is —SO2(C1-6alkyl).
In certain embodiments, q is 0.
Another aspect of this invention provides compounds wherein Q is pyridyl. In some embodiments, Q is
In some embodiments, Q is substituted with one occurrence of J and is
In some embodiments, Ja is H, C1-4alkyl; Jb is C1-4alkyl; and Jc is CN. In other embodiments, Ja is H, methyl, or ethyl; Jb is methyl or ethyl; or Ja and Jb join together to form cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, tetrahydropyranyl, or quinuclidinyl ring.
Another aspect of this invention provides compounds wherein Q is
In some embodiments, Q is substituted with occurrence of J and is
In some embodiments, J is C1-10aliphatic, —(C1-4alkyl)-CF3, —(C1-4alkyl)-(C3-C6cycloaliphatic), —(C1-4alkyl)-N(C1-3alkyl)2, —(C1-4alkyl)-O(C1-3alkyl), C3-C6cycloaliphatic, or tetrahydrofuranyl.
In some embodiments, p is 0 or 1. In some embodiments, p is 0. In other embodiments, p is 1.
One aspect of the invention provides compounds wherein R1 is halo, CN, NO2 or X. In some embodiments, X is N(R4)2, —(C1-3alkyl)-N(R4)2, OR4, —(C1-3alkyl)-OR4, —O—(C1-3alkyl)-N(R4)2, or —NR4—(C1-3alkyl)-N(R4)2; R4 is H or C1-4alkyl. In other embodiments, X is halo, CN, NO2, CH2NH2, NH2, NHCH3, NHCH2CH3, N(CH3)2, OCH2CH2N(CH3)2, CH2CH2OH, NHCH2CH2N(CH3)2, NH—(CH2)2NH2, or N(CH3)(CH2)3N(CH3)2.
Another aspect provides compounds wherein R1 is Q1. In some embodiments, R1 is a 4-7 membered heterocyclic ring having 1-2 nitrogen atoms. In other embodiments, R1 is pyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, or homopiperazinyl.
Another aspect provides compounds wherein R1 is X-Q1. In some embodiments, X is NR*. In other embodiments, Q1 is a 4-7 membered heterocyclic ring having 1-2 heteroatoms selected from nitrogen, oxygen, or sulfur. In yet other embodiments, R1 is N(CH3)piperidinyl, NH—(CH2)2(morpholinyl), NH-azetidinyl, or NH-piperidinyl.
In some embodiments, JQ1 is C1-3alkyl wherein up to one methylene unit is replaced with nitrogen. In other embodiments, JQ1 is CH2NH2, NH2, or N(CH3)2.
Another embodiment provides a compound selected from the following:
In some embodiments, the variables are as depicted in the compounds of the disclosure including compounds in the table(s) above.
Compounds of this invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
As described herein, a specified number range of atoms includes any integer therein. For example, a group having from 1-4 atoms could have 1, 2, 3, or 4 atoms.
As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally herein, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
Unless otherwise indicated, a substituent connected by a bond drawn from the center of a ring means that the substituent can be bonded to any position in the ring. In example i below, for instance, J1 can be bonded to any position on the pyridyl ring. For bicyclic rings, a bond drawn through both rings indicates that the substituent can be bonded from any position of the bicyclic ring. In example ii below, for instance, J1 can be bonded to the 5-membered ring (on the nitrogen atom, for instance), and to the 6-membered ring.
The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched), branched, or cyclic, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation that has a single point of attachment to the rest of the molecule.
Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Aliphatic groups may be linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, vinyl, n-butenyl, ethynyl, and tert-butyl. Aliphatic groups may also be cyclic, or have a combination of linear or branched and cyclic groups. Examples of such types of aliphatic groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, —CH2-cyclopropyl, CH2CH2CH(CH3)-cyclohexyl.
The term “cycloaliphatic” (or “carbocycle” or “carbocyclyl”) refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. Examples of cycloaliphatic groups include, but are not limited to, cycloalkyl and cycloalkenyl groups. Specific examples include, but are not limited to, cyclohexyl, cyclopropenyl, and cyclobutyl.
The term “heterocycle”, “heterocyclyl”, or “heterocyclic” as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members are an independently selected heteroatom. In some embodiments, the “heterocycle”, “heterocyclyl”, or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
Examples of heterocycles include, but are not limited to, 3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and 1,3-dihydro-imidazol-2-one.
Cyclic groups, (e.g. cycloaliphatic and heterocycles), can be linearly fused, bridged, or spirocyclic.
The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl)).
The term “unsaturated”, as used herein, means that a moiety has one or more units of unsaturation. As would be known by one of skill in the art, unsaturated groups can be partially unsaturated or fully unsaturated. Examples of partially unsaturated groups include, but are not limited to, butene, cyclohexene, and tetrahydropyridine. Fully unsaturated groups can be aromatic, anti-aromatic, or non-aromatic. Examples of fully unsaturated groups include, but are not limited to, phenyl, cyclooctatetraene, pyridyl, thienyl, and 1-methylpyridin-2(1H)-one.
The term “alkoxy”, or “thioalkyl”, as used herein, refers to an alkyl group, as previously defined, attached through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom.
The terms “haloalkyl”, “haloalkenyl”, “haloaliphatic”, and “haloalkoxy” mean alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. This term includes perfluorinated alkyl groups, such as —CF3 and —CF2CF3.
The terms “halogen”, “halo”, and “hal” mean F, Cl, Br, or I.
The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring”.
The term “heteroaryl”, used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term “heteroaryl” may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”. Examples of heteroaryl rings include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).
It shall be understood that the term “heteroaryl” includes certain types of heteroaryl rings that exist in equilibrium between two different forms. More specifically, for example, species such hydropyridine and pyridinone (and likewise hydroxypyrimidine and pyrimidinone) are meant to be encompassed within the definition of “heteroaryl.”
The term “protecting group” and “protective group” as used herein, are interchangeable and refer to an agent used to temporarily block one or more desired functional groups in a compound with multiple reactive sites. In certain embodiments, a protecting group has one or more, or preferably all, of the following characteristics: a) is added selectively to a functional group in good yield to give a protected substrate that is b) stable to reactions occurring at one or more of the other reactive sites; and c) is selectively removable in good yield by reagents that do not attack the regenerated, deprotected functional group. As would be understood by one skilled in the art, in some cases, the reagents do not attack other reactive groups in the compound. In other cases, the reagents may also react with other reactive groups in the compound. Examples of protecting groups are detailed in Greene, T. W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999 (and other editions of the book), the entire contents of which are hereby incorporated by reference. The term “nitrogen protecting group”, as used herein, refers to an agent used to temporarily block one or more desired nitrogen reactive sites in a multifunctional compound. Preferred nitrogen protecting groups also possess the characteristics exemplified for a protecting group above, and certain exemplary nitrogen protecting groups are also detailed in Chapter 7 in Greene, T. W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.
In some embodiments, a methylene unit of an alkyl or aliphatic chain is optionally replaced with another atom or group. Examples of such atoms or groups include, but are not limited to, nitrogen, oxygen, sulfur, —C(O)—, —C(═N—CN)—, —C(═NR)—, —C(═NOR)—, —SO—, and —SO2—. These atoms or groups can be combined to form larger groups. Examples of such larger groups include, but are not limited to, —OC(O)—, —C(O)CO—, —CO2—, —C(O)NR—, —C(═N—CN), —NRCO—, —NRC(O)O—, —SO2NR—, —NRSO2—, —NRC(O)NR—, —OC(O)NR—, and —NRSO2NR—, wherein R is, for example, H or C1-6aliphatic. It should be understood that these groups can be bonded to the methylene units of the aliphatic chain via single, double, or triple bonds. An example of an optional replacement (nitrogen atom in this case) that is bonded to the aliphatic chain via a double bond would be —CH2CH═N—CH3. In some cases, especially on the terminal end, an optional replacement can be bonded to the aliphatic group via a triple bond. One example of this would be CH2CH2CH2C≡N. It should be understood that in this situation, the terminal nitrogen is not bonded to another atom.
It should also be understood that, the term “methylene unit” can also refer to branched or substituted methylene units. For example, in an isopropyl moiety [—CH(CH3)2], a nitrogen atom (e.g. NR) replacing the first recited “methylene unit” would result in dimethylamine [—N(CH3)2]. In instances such as these, one of skill in the art would understand that the nitrogen atom will not have any additional atoms bonded to it, and the “R” from “NR” would be absent in this case.
The term “metal-mediated reaction”, as used herein, refers to a reaction in which a carbon-carbon bond or carbon nitrogen bond is formed with the aid of a metal catalyst. Examples of metal-mediated reactions that form carbon-carbon bonds include, but are not limited to, Suzuki couplings, Stille couplings, and Negishi couplings. Examples of metal-mediated reactions that form carbon-nitrogen bonds such as Buchwald couplings and Buchwald Hartwig couplings.
Examples of cross coupling groups and their respective metal-mediated conditions include, but are not limited to, boronic acids and boronic esters with Suzuki coupling conditions, SnBu3 with Stille coupling conditions, ZnX with Negishi coupling conditions (wherein X is halo), or an aryl or vinyl halide or terminal alkyne with Sonogashira coupling conditions. All these coupling conditions typically involve the use of a catalyst, a suitable solvent, and optionally a base.
Suzuki coupling conditions involve the use of a palladium catalyst and a suitable solvent. Examples of suitable palladium catalysts include, but are not limited to, PdCl2(PPh3)2, Pd(Ph3)4, and PdCl2(dppf). Suitable bases include, but are not limited to, K2CO3 and Na2CO3. Suitable solvents include, but are not limited to, tetrahydrofuran, toluene, and ethanol.
Stille coupling conditions involve the use of a catalyst (usually palladium, but sometimes nickel), a suitable solvent, and other optional reagents. Examples of suitable catalysts include, but are not limited to, PdCl2(PPh3)2, Pd(Ph3)4, and PdCl2(dppf). Suitable solvents include, but are not limited to, tetrahydrofuran, toluene, and dimethylformamide.
Negishi coupling conditions involve the use of a catalyst (palladium or nickel) and a suitable solvent. Examples of suitable catalysts include, but are not limited to Pd2(dba)3, Ni(PPh3)2Cl2, PdCl2(PPh3)2, and Pd(Ph3)4. Suitable solvents include, but are not limited to, tetrahydrofuran, toluene, and dimethylformamide.
Sonogashira coupling conditions involve the use of a catalyst (palladium or copper), an optional base, and a suitable solvent. Examples of suitable catalysts include, but are not limited to CuI, Pd(Ph3)4 and PdCl2(PPh3)2. Suitable solvents include, but are not limited to, diethylamine, triethylamine, and DMF. Optional bases include diethylamine, triethylamine, K2CO3, or Cs2CO3.
Buchwald or Buchwald-Hartwig coupling conditions involve the use of a palladium catalyst, a base, and a suitable solvent. Examples of suitable catalysts include, but are not limited to (Pd[P(o-Tolyl)3]2), Pd2(dba)3 and Pd(dba)2. Suitable solvents include, but are not limited to, toluene, dioxane, and THF. Optional bases include NaOtBu or LiHMDS. Sometimes, a bidentate phosphate ligand, such as BINAP or DPPF, can also be included.
Suzuki, Stille, Sonogashira, Negishi, Buchwald, and Buchwald-Hartwig conditions are known to one skilled in the art and are described in more detail in a variety of references.
Unless otherwise indicated, the optional replacements form a chemically stable compound. Optional replacements can occur both within the chain and/or at either end of the chain; i.e. both at the point of attachment and/or also at the terminal end. Two optional replacements can also be adjacent to each other within a chain so long as it results in a chemically stable compound. For example, a C4 aliphatic can be optionally replaced by 2 nitrogen atoms to form —CH2—N═N—CH2—. The optional replacements can also completely replace all of the carbon atoms in a chain. For example, a C3 aliphatic can be optionally replaced by —NR—, —C(O)—, and —NR— to form —NRC(O)NR— (a urea).
Unless otherwise indicated, if the replacement occurs at the terminal end, the replacement atom is bound to a hydrogen atom on the terminal end. For example, if a methylene unit of —CH2CH2CH3 were optionally replaced with —O—, the resulting compound could be —OCH2CH3, —CH2OCH3, or —CH2CH2OH. It should be understood that if the terminal atom does not contain any free valence electrons, then a hydrogen atom is not required at the terminal end (e.g., —CH2CH2CH═O or —CH2CH2C≡N).
Unless otherwise indicated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, geometric, conformational, and rotational) forms of the structure. For example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers are included in this invention. As would be understood to one skilled in the art, a substituent can freely rotate around any rotatable bonds. For example, a substituent drawn as
also represents
Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, geometric, conformational, and rotational mixtures of the present compounds are within the scope of the invention.
Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
Additionally, unless otherwise indicated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
Pharmaceutically Acceptable Salts
The compounds of this invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable salt.
A “pharmaceutically acceptable salt” means any non-toxic salt of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of the ATR protein kinase.
Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. These salts can be prepared in situ during the final isolation and purification of the compounds. Acid addition salts can be prepared by 1) reacting the purified compound in its free-based form with a suitable organic or inorganic acid and 2) isolating the salt thus formed.
Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
Base addition salts can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed. Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and N+(C1-4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. Other acids and bases, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid or base addition salts.
The following abbreviations are used:
DMSO dimethyl sulfoxide
ATP adenosine triphosphate
1HNMR proton nuclear magnetic resonance
HPLC high performance liquid chromatography
LCMS liquid chromatography-mass spectrometry
TLC thin layer chromatography
Rt retention time
Compound Uses
One aspect of this invention provides compounds that are inhibitors of ATR kinase, and thus are useful for treating or lessening the severity of a disease, condition, or disorder where ATR is implicated in the disease, condition, or disorder.
Another aspect of this invention provides compounds that are useful for the treatment of diseases, disorders, and conditions characterized by excessive or abnormal cell proliferation. Such diseases include, a proliferative or hyperproliferative disease. Examples of proliferative and hyperproliferative diseases include, without limitation, cancer and myeloproliferative disorders.
In some embodiments, said compounds are selected from the group consisting of a compound of formula I. The term “cancer” includes, but is not limited to the following cancers. Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell; lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; undifferentiated thyroid cancer, medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.
In some embodiments, the cancer is selected from a cancer of the lung or the pancreas. In other embodiments, the cancer is selected from lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, or brain cancer. In yet other embodiments, the cancer is selected from non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.
Thus, the term “cancerous cell” as provided herein, includes a cell afflicted by any one of the above-identified conditions. In some embodiments, the cancer is selected from colorectal, thyroid, or breast cancer.
The term “myeloproliferative disorders”, includes disorders such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, systemic mast cell disease, and hematopoietic disorders, in particular, acute-myelogenous leukemia (AML), chronic-myelogenous leukemia (CML), acute-promyelocytic leukemia (APL), and acute lymphocytic leukemia (ALL).
Pharmaceutically Acceptable Derivatives or Prodrugs
In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the herein identified disorders.
The compounds of this invention can also exist as pharmaceutically acceptable derivatives.
A “pharmaceutically acceptable derivative” is an adduct or derivative which, upon administration to a patient in need, is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof. Examples of pharmaceutically acceptable derivatives include, but are not limited to, esters and salts of such esters.
A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable ester, salt of an ester or other derivative or salt thereof of a compound, of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favoured derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.
Pharmaceutical Compositions
The present invention also provides compounds and compositions that are useful as inhibitors of ATR kinase.
One aspect of this invention provides pharmaceutically acceptable compositions that comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
The pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Combination Therapies
Another aspect of this invention is directed towards a method of treating cancer in a subject in need thereof, comprising administration of a compound of this invention or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent. In some embodiments, said method comprises the sequential or co-administration of the compound or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent.
In some embodiments, said additional therapeutic agent is an anti-cancer agent. In other embodiments, said additional therapeutic agent is a DNA-damaging agent. In yet other embodiments, said additional therapeutic agent is selected from radiation therapy, chemotherapy, or other agents typically used in combination with radiation therapy or chemotherapy, such as radiosensitizers and chemosensitizers. In yet other embodiments, said additional therapeutic agent is ionizing radiation.
As would be known by one of skill in the art, radiosensitizers are agents that can be used in combination with radiation therapy. Radiosensitizers work in various different ways, including, but not limited to, making cancer cells more sensitive to radiation therapy, working in synergy with radiation therapy to provide an improved synergistic effect, acting additively with radiation therapy, or protecting surrounding healthy cells from damage caused by radiation therapy. Likewise chemosensitizers are agents that can be used in combination with chemotherapy. Similarly, chemosensitizers work in various different ways, including, but not limited to, making cancer cells more sensitive to chemotherapy, working in synergy with chemotherapy to provide an improved synergistic effect, acting additively to chemotherapy, or protecting surrounding healthy cells from damage caused by chemotherapy.
Examples of DNA-damaging agents that may be used in combination with compounds of this invention include, but are not limited to Platinating agents, such as Carboplatin, Nedaplatin, Satraplatin and other derivatives; Topo I inhibitors, such as Topotecan, irinotecan/SN38, rubitecan and other derivatives; Antimetabolites, such as Folic family (Methotrexate, Pemetrexed and relatives); Purine antagonists and Pyrimidine antagonists (Thioguanine, Fludarabine, Cladribine, Cytarabine, Gemcitabine, 6-Mercaptopurine, 5-Fluorouracil (5FU) and relatives); Alkylating agents, such as Nitrogen mustards (Cyclophosphamide, Melphalan, Chlorambucil, mechlorethamine, Ifosfamide and relatives); nitrosoureas (eg Carmustine); Triazenes (Dacarbazine, temozolomide); Alkyl sulphonates (eg Busulfan); Procarbazine and Aziridines; Antibiotics, such as Hydroxyurea, Anthracyclines (doxorubicin, daunorubicin, epirubicin and other derivatives); Anthracenediones (Mitoxantrone and relatives); Streptomyces family (Bleomycin, Mitomycin C, actinomycin); and Ultraviolet light.
Other therapies or anticancer agents that may be used in combination with the inventive agents of the present invention include surgery, radiotherapy (in but a few examples, gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes, to name a few), endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF) to name a few), hyperthermia and cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, the DNA damaging agents listed herein, spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), Gleevec™, adriamycin, dexamethasone, and cyclophosphamide.
A compound of the instant invention may also be useful for treating cancer in combination with any of the following therapeutic agents: abarelix (Plenaxis Depot®); aldesleukin (Prokine®); Aldesleukin (Proleukin®); Alemtuzumabb (Campath®); alitretinoin (Panretin®); allopurinol (Zyloprim®); altretamine (Hexalen®); amifostine (Ethyol®); anastrozole (Arimidex®); arsenic trioxide (Trisenox®); asparaginase (Elspar®); azacitidine (Vidaza®); bevacuzimab (Avastin®); bexarotene capsules (Targretin®); bexarotene gel (Targretin®); bleomycin (Blenoxane®); bortezomib (Velcade®); busulfan intravenous (Busulfex®); busulfan oral (Myleran®); calusterone (Methosarb®); capecitabine (Xeloda®); carboplatin (Paraplatin®); carmustine (BCNU®, BiCNU®); carmustine (Gliadel®); carmustine with Polifeprosan 20 Implant (Gliadel Wafer®); celecoxib (Celebrex®); cetuximab (Erbitux®); chlorambucil (Leukeran®); cisplatin (Platinol®); cladribine (Leustatin®, 2-CdA®); clofarabine (Clolar®); cyclophosphamide (Cytoxan®, Neosar®); cyclophosphamide (Cytoxan Injection®); cyclophosphamide (Cytoxan Tablet®); cytarabine (Cytosar-U®); cytarabine liposomal (DepoCyt®); dacarbazine (DTIC-Dome®); dactinomycin, actinomycin D (Cosmegen®); Darbepoetin alfa (Aranesp®); daunorubicin liposomal (DanuoXome®); daunorubicin, daunomycin (Daunorubicin®); daunorubicin, daunomycin (Cerubidine®); Denileukin diftitox (Ontak®); dexrazoxane (Zinecard®); docetaxel (Taxotere®); doxorubicin (Adriamycin PFS®); doxorubicin (Adriamycin®, Rubex®); doxorubicin (Adriamycin PFS Injection®); doxorubicin liposomal (Doxil®); dromostanolone propionate (Dromostanolone®); dromostanolone propionate (masterone Injection®); Elliott's B Solution (Elliott's B Solution®); epirubicin (Ellence®); Epoetin alfa (Epogen®); erlotinib (Tarceva®); estramustine (Emcyt®); etoposide phosphate (Etopophos®); etoposide, VP-16 (Vepesid®); exemestane (Aromasin®); Filgrastim (Neupogen®); floxuridine (intraarterial) (FUDR®); fludarabine (Fludara®); fluorouracil, 5-FU (Adrucil®); fulvestrant (Faslodex®); gefitinib (Iressa®); gemcitabine (Gemzar®); gemtuzumab ozogamicin (Mylotarg®); goserelin acetate (Zoladex Implant®); goserelin acetate (Zoladex®); histrelin acetate (Histrelin Implant®); hydroxyurea (Hydrea®); Ibritumomab Tiuxetan (Zevalin®); idarubicin (Idamycin®); ifosfamide (IFEX®); imatinib mesylate (Gleevec®); interferon alfa 2a (Roferon A®); Interferon alfa-2b (Intron A®); irinotecan (Camptosar®); lenalidomide (Revlimid®); letrozole (Femara®); leucovorin (Wellcovorin®, Leucovorin®); Leuprolide Acetate (Eligard®); levamisole (Ergamisol®); lomustine, CCNU (CeeBU®); meclorethamine, nitrogen mustard (Mustargen®); megestrol acetate (Megace®); melphalan, L-PAM (Alkeran®); mercaptopurine, 6-MP (Purinethol®); mesna (Mesnex®); mesna (Mesnex Tabs®); methotrexate (Methotrexate®); methoxsalen (Uvadex®); mitomycin C (Mutamycin®); mitotane (Lysodren®); mitoxantrone (Novantrone®); nandrolone phenpropionate (Durabolin-50®); nelarabine (Arranon®); Nofetumomab (Verluma®); Oprelvekin (Neumega®); oxaliplatin (Eloxatin®); paclitaxel (Paxene®); paclitaxel (Taxol®); paclitaxel protein-bound particles (Abraxane®); palifermin (Kepivance®); pamidronate (Aredia®); pegademase (Adagen (Pegademase Bovine)®); pegaspargase (Oncaspar®); Pegfilgrastim (Neulasta®); pemetrexed disodium (Alimta®); pentostatin (Nipent®); pipobroman (Vercyte®); plicamycin, mithramycin (Mithracin®); porfimer sodium (Photofrin®); procarbazine (Matulane®); quinacrine (Atabrine®); Rasburicase (Elitek®); Rituximab (Rituxan®); sargramostim (Leukine®); Sargramostim (Prokine®); sorafenib (Nexavar®); streptozocin (Zanosar®); sunitinib maleate (Sutent®); talc (Sclerosol®); tamoxifen (Nolvadex®); temozolomide (Temodar®); teniposide, VM-26 (Vumon®); testolactone (Teslac®); thioguanine, 6-TG (Thioguanine®); thiotepa (Thioplex®); topotecan (Hycamtin®); toremifene (Fareston®); Tositumomab (Bexxar®); Tositumomab/I-131 tositumomab (Bexxar®); Trastuzumab (Herceptin®); tretinoin, ATRA (Vesanoid®); Uracil Mustard (Uracil Mustard Capsules®); valrubicin (Valstar®); vinblastine (Velban®); vincristine (Oncovin®); vinorelbine (Navelbine®); zoledronate (Zometa®) and vorinostat (Zolinza®).
For a comprehensive discussion of updated cancer therapies see, http://www.nci.nih.gov/, a list of the FDA approved oncology drugs at http://www.fda.gov/cder/cancer/druglistframe.htm, and The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby incorporated by reference.
Compositions for Administration into a Subject
The ATR kinase inhibitors or pharmaceutical salts thereof may be formulated into pharmaceutical compositions for administration to animals or humans. These pharmaceutical compositions, which comprise an amount of the ATR inhibitor effective to treat or prevent the diseases or conditions described herein and a pharmaceutically acceptable carrier, are another embodiment of the present invention.
The exact amount of compound required for treatment will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.
In some embodiments, these compositions optionally further comprise one or more additional therapeutic agents. For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the compounds of this invention to treat proliferative diseases and cancer. Examples of known agents with which these compositions can be combined are listed above under the “Combination Therapies” section and also throughout the specification. Some embodiments provide a simultaneous, separate or sequential use of a combined preparation.
Modes of Administration and Dosage Forms
The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.
Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include, but are not limited to, lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
The amount of protein kinase inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of inhibitor will also depend upon the particular compound in the composition.
Administering with Another Agent
Depending upon the particular protein kinase-mediated conditions to be treated or prevented, additional drugs, which are normally administered to treat or prevent that condition, may be administered together with the compounds of this invention.
Those additional agents may be administered separately, as part of a multiple dosage regimen, from the protein kinase inhibitor-containing compound or composition. Alternatively, those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor in a single composition.
Another aspect of this invention is directed towards a method of treating cancer in a subject in need thereof, comprising the sequential or co-administration of a compound of this invention or a pharmaceutically acceptable salt thereof, and an anti-cancer agent. In some embodiments, said anti-cancer agent is selected from Platinating agents, such as Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, or Satraplatin and other derivatives; Topo I inhibitors, such as Camptothecin, Topotecan, irinotecan/SN38, rubitecan and other derivatives; Antimetabolites, such as Folic family (Methotrexate, Pemetrexed and relatives); Purine family (Thioguanine, Fludarabine, Cladribine, 6-Mercaptopurine and relatives); Pyrimidine family (Cytarabine, Gemcitabine, 5-Fluorouracil and relatives); Alkylating agents, such as Nitrogen mustards (Cyclophosphamide, Melphalan, Chlorambucil, mechlorethamine, Ifosfamide, and relatives); nitrosoureas (e.g. Carmustine); Triazenes (Dacarbazine, temozolomide); Alkyl sulphonates (e.g. Busulfan); Procarbazine and Aziridines; Antibiotics, such as Hydroxyurea; Anthracyclines (doxorubicin, daunorubicin, epirubicin and other derivatives); Anthracenediones (Mitoxantrone and relatives); Streptomyces family (Bleomycin, Mitomycin C, actinomycin) and Ultraviolet light.
Another embodiment provides administering a compound of this invention with an additional therapeutic agent that inhibits or modulates a base excision repair protein. In some embodiments, the base excision repair protein is selected from UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2 (Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin. In other embodiments, the base excision repair protein is selected from PARP1, PARP2, or PolB. In yet other embodiments, the base excision repair protein is selected from PARP1 or PARP2. In some embodiments, th agent is selected from Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also known as BSI-201 or SAR240550), Veliparib (also known as ABT-888), Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or AZD2461.
Biological Samples
As inhibitors of ATR kinase, the compounds and compositions of this invention are also useful in biological samples. One aspect of the invention relates to inhibiting ATR kinase activity in a biological sample, which method comprises contacting said biological sample with a compound described herein or a composition comprising said compound. The term “biological sample”, as used herein, means an in vitro or an ex vivo sample, including, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. The term “compounds described herein” includes compounds of formula I.
Inhibition of ATR kinase activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, and biological specimen storage.
Study of Protein Kinases
Another aspect of this invention relates to the study of protein kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such protein kinases; and the comparative evaluation of new protein kinase inhibitors. Examples of such uses include, but are not limited to, biological assays such as enzyme assays and cell-based assays.
The activity of the compounds as protein kinase inhibitors may be assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine inhibition of either the kinase activity or ATPase activity of the activated kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to the protein kinase and may be measured either by radiolabelling the inhibitor prior to binding, isolating the inhibitor/kinase complex and determining the amount of radiolabel bound, or by running a competition experiment where new inhibitors are incubated with the kinase bound to known radioligands. Detailed conditions for assaying a compound utilized in this invention as an inhibitor of ATR is set forth in the Examples below.
Another aspect of the invention provides a method for modulating enzyme activity by contacting a compound described herein with ATR kinase.
Methods of Treatment
In one aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where ATR kinase is implicated in the disease state. In another aspect, the present invention provides a method for treating or lessening the severity of an ATR kinase disease, condition, or disorder where inhibition of enzymatic activity is implicated in the treatment of the disease. In another aspect, this invention provides a method for treating or lessening the severity of a disease, condition, or disorder with compounds that inhibit enzymatic activity by binding to the ATR kinase. Another aspect provides a method for treating or lessening the severity of a kinase disease, condition, or disorder by inhibiting enzymatic activity of ATR kinase with an ATR kinase inhibitor.
One aspect of the invention relates to a method of inhibiting ATR kinase activity in a patient, which method comprises administering to the patient a compound described herein, or a composition comprising said compound. In some embodiments, said method is used to treat or prevent a condition selected from proliferative and hyperproliferative diseases, such as cancer.
Another aspect of this invention provides a method for treating, preventing, or lessening the severity of proliferative or hyperproliferative diseases comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound, to a subject in need thereof. In some embodiments, said subject is a patient. The term “patient”, as used herein, means an animal, preferably a human.
In some embodiments, said method is used to treat or prevent cancer. In some embodiments, said method is used to treat or prevent a type of cancer with solid tumors. In yet another embodiment, said cancer is selected from the following cancers: Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.
In some embodiments, the cancer is selected from the cancers described herein. In some embodiments, said cancer is lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, or brain cancer. In other embodiments, the cancer is selected from a cancer of the lung or the pancreas.
In yet other embodiments, the cancer is selected from non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.
In certain embodiments, an “effective amount” of the compound or pharmaceutically acceptable composition is that amount effective in order to treat said disease. The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of said disease.
One aspect provides a method for inhibiting ATR in a patient comprising administering a compound described herein as described herein. Another embodiment provides a method of treating cancer comprising administering to a patient a compound described herein, wherein the variables are as defined herein.
Some embodiments comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.
In some embodiments, said DNA-damaging agent is selected from ionizing radiation, radiomimetic neocarzinostatin, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent, an alkyl sulphonates, an antimetabolite, or an antibiotic. In other embodiments, said DNA-damaging agent is selected from ionizing radiation, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, or an antibiotic.
Examples of Platinating agents include Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, Satraplatin and other derivatives. Other platinating agents include Lobaplatin, and Triplatin. Other platinating agents include Tetranitrate, Picoplatin, Satraplatin, ProLindac and Aroplatin.
Examples of Topo I inhibitor include Camptothecin, Topotecan, irinotecan/SN38, rubitecan and other derivatives. Other Topo I inhibitors include Belotecan.
Examples of Topo II inhibitors include Etoposide, Daunorubicin, Doxorubicin, Aclarubicin, Epirubicin, Idarubicin, Amrubicin, Pirarubicin, Valrubicin, Zorubicin and Teniposide.
Examples of Antimetabolites include members of the Folic family, Purine family (purine antagonists), or Pyrimidine family (pyrimidine antagonists). Examples of the Folic family include methotrexate, pemetrexed and relatives; examples of the Purine family include Thioguanine, Fludarabine, Cladribine, 6-Mercaptopurine, and relatives; examples of the Pyrimidine family include Cytarabine, gemcitabine, 5-Fluorouracil (5FU) and relatives.
Some other specific examples of antimetabolites include Aminopterin, Methotrexate, Pemetrexed, Raltitrexed, Pentostatin, Cladribine, Clofarabine, Fludarabine, Thioguanine, Mercaptopurine, Fluorouracil, Capecitabine, Tegafur, Carmofur, Floxuridine, Cytarabine, Gemcitabine, Azacitidine and Hydroxyurea.
Examples of alkylating agents include Nitrogen mustards, Triazenes, alkyl sulphonates, Procarbazine and Aziridines. Examples of Nitrogen mustards include Cyclophosphamide, Melphalan, Chlorambucil and relatives; examples of nitrosoureas include Carmustine; examples of triazenes include Dacarbazine and temozolomide; examples of alkyl sulphonates include Busulfan.
Other specific examples of alkylating agents include Mechlorethamine, Cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine, Estramustine, Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan, Treosulfan, Carboquone, ThioTEPA, Triaziquone, Triethylenemelamine, Procarbazine, Dacarbazine, Temozolomide, Altretamine, Mitobronitol, Actinomycin, Bleomycin, Mitomycin and Plicamycin.
Examples of antibiotics include Mitomycin, Hydroxyurea; Anthracyclines, Anthracenediones, Streptomyces family. Examples of Anthracyclines include doxorubicin, daunorubicin, epirubicin and other derivatives; examples of Anthracenediones include Mitoxantrone and relatives; examples of Streptomyces family include Bleomycin, Mitomycin C, and actinomycin.
In certain embodiments, said platinating agent is Cisplatin or Oxaliplatin; said Topo I inhibitor is Camptothecin; said Topo II inhibitor is Etoposide; and said antibiotic is Mitomycin. In other embodiments, said platinating agent is selected from Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, or Satraplatin; said Topo I inhibitor is selected from Camptothecin, Topotecan, irinotecan/SN38, rubitecan; said Topo II inhibitor is selected from Etoposide; said antimetabolite is selected from a member of the Folic Family, the Purine Family, or the Pyrimidine Family; said alkylating agent is selected from nitrogen mustards, nitrosoureas, triazenes, alkyl sulfonates, Procarbazine, or aziridines; and said antibiotic is selected from Hydroxyurea, Anthracyclines, Anthracenediones, or Streptomyces family.
In some embodiments, the additional therapeutic agent is ionizing radiation. In other embodiments, the additional therapeutic agent is Cisplatin or Carboplatin. In yet other embodiments, the additional therapeutic agent is Etoposide. In yet other embodiments, the additional therapeutic agent is Temozolomide.
In certain embodiments, the additional therapeutic agent is selected from one or more of the following: Cisplatin, Carboplatin, gemcitabine, Etoposide, Temozolomide, or ionizing radiation.
Another embodiment provides methods for treating pancreatic cancer by administering a compound described herein in combination with another known pancreatic cancer treatment. One aspect of the invention includes administering a compound described herein in combination with gemcitabine. In some embodiments, the pancreatic cancer comprises one of the following cell lines: PSN-1, MiaPaCa-2 or Panc-1. According to another aspect, the cancer comprises one of the following primary tumor lines: Panc-M or MRC5.
Another aspect of the invention includes administering a compound described herein in combination with radiation therapy. Yet another aspect provides a method of abolishing radiation-induced G2/M checkpoint by administering a compound described herein in combination with radiation treatment.
Another aspect provides a method of treating pancreatic cancer by administering to pancreatic cancer cells a compound described herein in combination with one or more cancer therapies. In some embodiments, the compound is combined with chemoradiation, chemotherapy, and/or radiation therapy. As would be understood by one of skill in the art, chemoradiation refers to a treatment regime that includes both chemotherapy (such as gemcitabine) and radiation. In some embodiments, the chemotherapy comprises gemcitabine.
In some embodiments, the chemotherapy is gemcitabine.
Yet another aspect provides a method of increasing the sensitivity of pancreatic cancer cells to a cancer therapy selected from gemcitabine or radiation therapy by administering a compound described herein in combination with the cancer therapy.
In some embodiments, the cancer therapy comprises gemcitabine. In other embodiments, the cancer therapy comprises radiation therapy. In yet another embodiment the cancer therapy comprises chemoradiation.
In some embodiments, the cancer therapy is gemcitabine. In other embodiments, the cancer therapy is radiation therapy. In yet another embodiment the cancer therapy is chemoradiation.
Another aspect provides a method of inhibiting phosphorylation of Chk1 (Ser 345) in a pancreatic cancer cell comprising administering a compound described herein after treatment with gemcitabine (100 nM) and/or radiation (6 Gy) to a pancreatic cancer cell.
Another aspect provides method of radiosensitizing hypoxic PSN-1, MiaPaCa-2 or PancM tumor cells by administering a compound described herein to the tumor cell in combination with radiation therapy.
Yet another aspect provides a method of sensitizing hypoxic PSN-1, MiaPaCa-2 or PancM tumor cells by administering a compound described herein to the tumor cell in combination with gemcitabine.
Another aspect provides a method of sensitizing PSN-1 and MiaPaCa-2 tumor cells to chemoradiation by administering a compound described herein to the tumor cells in combination with chemoradiation.
Another aspect provides a method of disrupting damage-induced cell cycle checkpoints by administering a compound described herein in combination with radiation therapy to a pancreatic cancer cell.
Another aspect provides a method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering a compound described herein in combination with one or more of the following treatments: chemoradiation, chemotherapy, and radiation therapy.
In some embodiments, the chemotherapy is gemcitabine.
Another aspect provides a method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering a compound described herein in combination with gemcitabine and radiation therapy.
In some embodiments, the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or Panc-1.
In other embodiments, the pancreatic cancer cells are in a cancer patient.
Another aspect of the invention provides a method of treating non-small cell lung cancer comprising administering to a patient a compound described herein in combination with one or more of the following additional therapeutic agents: Cisplatin or Carboplatin, Etoposide, and ionizing radiation. Some embodiments comprise administering to a patient a compound described herein in combination with Cisplatin or Carboplatin, Etoposide, and ionizing radiation. In some embodiments the combination is Cisplatin, Etoposide, and ionizing radiation. In other embodiments the combination is Carboplatin, Etoposide, and ionizing radiation.
Another embodiment provides a method of promoting cell death in cancer cells comprising administering to a patient a compound described herein, or a composition comprising said compound.
Yet another embodiment provides a method of preventing cell repair of DNA damage in cancer cells comprising administering to a patient a compound described herein, or a composition comprising said compound. Yet another embodiment provides a method of preventing cell repair caused by of DNA damage in cancer cells comprising administering to a patient a compound of formula I, or composition comprising said compound.
Another embodiment provides a method of sensitizing cells to DNA damaging agents comprising administering to a patient a compound described herein, or a composition comprising said compound.
In some embodiments, the method is used on a cancer cell having defects in the ATM signaling cascade. In some embodiments, said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1. In other embodiments, said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 or H2AX. According to another embodiment, the method is used on a cancer, cancer cell, or cell expressing DNA damaging oncogenes.
In another embodiment, the cell is a cancer cell expressing DNA damaging oncogenes. In some embodiments, said cancer cell has altered expression or activity of one or more of the following: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A and Rb.
According to another embodiment, the method is used on a cancer, cancer cell, or cell has a defect in a protein involved in base excision repair (“base excision repair protein”). There are many methods known in the art for determining whether a tumor has a defect in base excision repair. For example, sequencing of either the genomic DNA or mRNA products of each base excision repair gene (e.g., UNG, PARP1, or LIG1) can be performed on a sample of the tumor to establish whether mutations expected to modulate the function or expression of the gene product are present (Wang et al., Cancer Research 52:4824 (1992)). In addition to the mutational inactivation, tumor cells can modulate a DNA repair gene by hypermethylating its promoter region, leading to reduced gene expression. This is most commonly assessed using methylation-specific polymerase chain reaction (PCR) to quantify methylation levels on the promoters of base excision repair genes of interest. Analysis of base excision repair gene promoter methylation is available commercially (http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-421A.html).
Finally, the expression levels of base excision repair genes can be assessed by directly quantifying levels of the mRNA and protein products of each gene using standard techniques such as quantitative reverse transcriptase-coupled polymerase chain reaction (RT-PCR) and immunhohistochemistry (IHC), respectively (Shinmura et al., Carcinogenesis 25: 2311 (2004); Shinmura et al., Journal of Pathology 225:414 (2011)).
In some embodiments, the base excision repair protein is UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2 (Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin.
In some embodiments, the base excision repair protein is PARP1, PARP2, or PolB. In other embodiments, the base excision repair protein is PARP1 or PARP2.
The methods described above (gene sequence, promoter methylation and mRNA expression) may also be used to characterize the status (e.g., expression or mutation) of other genes or proteins of interesting, such DNA-damaging oncogenes expressed by a tumor or defects in the ATM signaling cascade of a cell.
Yet another embodiment provides use of a compound described herein as a radio-sensitizer or a chemo-sensitizer.
Yet other embodiment provides use of a compound of formula I as a single agent (monotherapy) for treating cancer. In some embodiments, the compounds of formula I are used for treating patients having cancer with a DNA-damage response (DDR) defect. In other embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX.
Compounds and Compositions for Use
One embodiment provides a compound or composition as described herein for use as a radio-sensitizer or a chemo-sensitizer. Another embodiment provides a compound or composition as described herein for use as a single agent (monotherapy) for treating cancer.
Another embodiment provides a compound or composition as described herein for treating patients having cancer with a DNA-damage response (DDR) defect. In some embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX. In other embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.
Another embodiment provides compounds or compositions described herein for treating cancer. In some embodiments, the compound or composition is further combined with an additional therapeutic agent described herein. In some embodiments, the compound or composition is further combined with a DNA damaging agent described herein.
In some embodiments, the cancer has a defect in a pathway described herein.
Manufacture of Medicaments
One embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for use as a radio-sensitizer or a chemo-sensitizer. Another embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for the manufacture of a medicament for use as a single agent (monotherapy) for treating cancer.
Yet another embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for the manufacture of a medicament for treating patients having cancer with a DNA-damage response (DDR) defect.
In some embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX. In other embodiments, said defect is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.
Another embodiment provides the use of a compound or composition described herein for the manufacture of a medicament for treating cancer. In some embodiments, the compound or composition is combined with an additional therapeutic agent, such as a DNA damaging agent, described herein. In another embodiment, the cancer has a defect in a pathway described herein.
The compounds of the disclosure may be prepared in light of the specification using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) and NMR (nuclear magnetic resonance). Below are a set of generic schemes that illustrate generally how to prepare the compounds of the present disclosure.
Scheme A depicts a general method for making compounds of Formula I.
Compound A is functionalised via either an SNAr reaction or a range of known metal mediated reactions such as, but not limited to, Suzuki couplings, Stille couplings, Buchwald-Hartwig coupling reactions to give compounds of Formula A-i. Where appropriate, J substituents on Ring Q can undergo further functionalisation by known reactions such as, but not limited to, Mitsunobu reactions and acylation.
These compounds are then brominated under standard conditions known to those skilled in the art such as, but not limited to, treatment with N-bromosuccinimide to give compounds of Formula A-ii. Reaction of these compounds under Sonogashira conditions with a suitable protected alkyne gives rise to compounds of the Formula A-iii. Suitable alkyne protecting groups PG include, but are not limited to, trimethylsilyl (TMS), TES or TIPS. These groups can be deprotected using conventional methods (e.g., aqueous sodium carbonate) to deprotect a TMS group to give compounds of Formula A-iv.
Compound A-iv can be cyclised to the corresponding pyrrolo[2,3-b]pyrazine of Formula A-v using methods known to those skilled in the art such as, but not limited to heating with KOtBu in NMP. Under certain circumstances, the protecting group PG of Compound A-iii can be removed concurrently with cyclisation to pyrrolo[2,3-b]pyrazine of Formula A-v, without need to isolate compounds of Formula A-iv.
Compounds of Formula A-v can be iodinated under standard conditions known to those skilled in the art such as, but not limited to, treatment with ICl to give compounds of Formula A-vi. Compounds of Formula A-vi are then protected with a suitable protecting group PG′ such as, but not limited to tosyl (p-toluenesulfonyl) or triphenylmethyl (“trityl”), to give compounds of Formula A-vii. These compounds are functionalised using a range of known metal mediated reactions such as, but not limited to, Buchwald couplings, Buchwald-Hartwig couplings, and Goldberg couplings to give compounds of Formula A-viii.
Where appropriate, substituents on at R1 can undergo further functionalisation by reactions known to those skilled in the art such as, but not limited to, Mitsunobu reactions, nucleophilic displacement and acylation. The protecting group PG′ can be removed under standard conditions known to those skilled in the art such as, but not limited to, treatment with aqueous base or TBAF when PG′ is tosyl (p-toluenesulfonyl) or hydrogenation when PG′ is a trityl group to give compounds of Formula I.
Scheme B depicts an alternative general method for making compounds of Formula I. Reaction of compound B under Sonogashira conditions with a suitable protected alkyne gives rise to compounds of the Formula B-i. Suitable alkyne protecting groups PG include, but are not limited to, TMS, TES or TIPS. The protecting group PG can be removed concurrently with cyclisation to pyrrolo[2,3-b]pyrazine of Formula B-ii using standard conditions known to those skilled in the art such as, but not limited to, treatment with KOtBu in NMP to give compounds of Formula B-ii. Compounds of Formula B-ii can be nitrated under standard conditions known to those skilled in the art such as, but not limited to, treatment with H2SO4 and conc. HNO3 to give compounds of Formula B-iii. Compounds of Formula B-iii are then protected with a suitable protecting group PG′ such as, but not limited to trityl, to give compounds of Formula B-iv. These compounds are reduced under standard conditions known to those skilled in the art such as, but not limited to, treatment with dichlorotin dihydrate, acetic acid and conc. HCl or Indium and HCl, to give compounds of Formula B-v. These compounds undergo coupling followed by cyclisation to give compounds of Formula B-vi using standard conditions known to those skilled in the art such as, but not limited to, treatment with an acid chloride, treating with an acid and oxalyl chloride, or treating with an acid using standard amide coupling reagents such as HOBT, EDC, CDI, or TBTU followed by dehydration or alkylation. Compounds B-vi and B-viii can be functionalised via either an SNAr reaction or a range of known metal mediated reactions such as, but not limited to, Suzuki couplings, Stille couplings, Buchwald-Hartwig coupling reactions to give compounds of Formula B-ix. The protecting group PG′ can be removed under standard conditions known to those skilled in the art such as, but not limited to, treatment with trifluoroacetic acid and triethylsilane to give compounds of Formula I.
Alternatively, Compounds of Formula B-iii are reduced under standard conditions known to those skilled in the art such as, but not limited to, treatment with dichlorotin dihydrate, acetic acid and conc. HCl or Indium and HCl, to give compounds of Formula B-vii. These compounds undergo coupling followed by cyclisation to give compounds of Formula B-viii using standard conditions known to those skilled in the art such as, but not limited to, treatment with an acid chloride, treating with an acid and oxalyl chloride, or treating with an acid using standard amide coupling reagents such as HOBT, EDC, CDI, or TBTU followed by dehydration or alkylation. Compound B-viii is functionalised via either an SNAr reaction or a range of known metal mediated reactions such as, but not limited to, Suzuki reactions, Stille couplings, Buchwald reactions, and Buchwald-Hartwig reactions to give compounds of Formula I.
According, another embodiment provides a process for preparing a compound of formula I:
wherein R1, R3, Q, J, J1, p, q, and n are as defined herein; comprising one or more of the following steps:
with a compound of formula X:
wherein G is either absent or an appropriate cross coupling group; under suitable metal-mediated reaction conditions such as Suzuki coupling, Stille coupling, or Buchwald-Hartwig coupling reaction conditions; or other type of reaction conditions such as SNAr reaction conditions to give compounds of Formula A-i
wherein Q, J, J1, and q are as defined herein;
wherein PG is a suitable nitrogen protecting group such as TMS, TES or TIPS; and Q, J, J1, and q are as defined herein;
wherein Q, J, J1, and q are as defined herein;
wherein Q, J, J1, and q are as defined herein 1;
wherein Q, J, J1, and q are as defined herein;
wherein PG′ is a suitable nitrogen protecting group, such as p-toluenesulfonyl or trityl, and Q, J, J1, and q are as defined herein;
wherein R1, R3, p, and n are as defined herein; under suitable metal-mediated coupling conditions to form a compound of formula A-viii. Suitable metal-mediated coupling conditions include, but are not limited to, Buchwald couplings to give compounds of Formula A-vii;
wherein PG′ is a suitable nitrogen protecting group and A, J, J1, and q are as defined herein; under suitable deprotection conditions to form a compound of formula I. Examples of suitable deprotection conditions are known to one of skill in the art and include, but are not limited to, treatment with aqueous base or TBAF when PG′ is tosyl (p-toluenesulfonyl) or hydrogenation when PG′ is a trityl group to give compounds of Formula I.
Another embodiment provides a process for preparing a compound of formula I:
wherein R1, R3, Q, J, J1, p, q, and n are as defined herein; comprising one or more of the following steps:
under Sonogashira conditions with a suitable protected alkyne (H—≡—PG) to form a compound of formula B-i:
wherein PG is TMS, TES, or TIPS;
Another embodiment provides a process for preparing a compound of formula I:
wherein R1, R3, Q, J, J1, p, q, and n as defined herein;
comprising one or more of the following steps:
wherein PG′ is a suitable nitrogen protecting group such as triphenylmethyl (trityl);
in the presence of a suitable solvent (such as THF) and optionally a base (such as DIPEA or TEA) to form a compound of formula B-vi:
wherein G is either absent or an appropriate cross coupling group; under suitable metalmediated reaction conditions such as Suzukicoupling, Stille couplings, or Buchwald-Hartwig coupling reactions conditions; or other type of reactions such as SNAr reaction conditions to form a compound of formula B-ix;
R1, R3, Q, J, J1, p, q, and n are as defined herein;
Another embodiment provides a process for preparing a compound of formula I:
wherein R1, R3, Q, J, J1, p, q, and n are as defined herein; comprising one or more of the following steps:
wherein G is either absent or an appropriate cross coupling group; under suitable metal-mediated reaction conditions (e.g., Suzuki coupling, Stille coupling, or Buchwald-Hartwig coupling reaction conditions); or other type of reaction conditions (e.g., SNAr reactions) to form a compound of formula I.
In some embodiments, the metal mediated coupling is a Suzuki coupling, wherein G is a boronic acid such as —B(OH)2 or a boronic ester known in the art for use in Suzuki coupling reactions.
In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way. 1H-NMR spectra were recorded at 400 MHz using a Bruker DPX 400 instrument. Mass spec. samples were analyzed on a MicroMass Quattro Micro mass spectrometer operated in single MS mode with electrospray ionization.
5-Bromopyrazin-2-amine (5 g, 28.74 mmol), (4-isopropylsulfonylphenyl) boronic acid (7.866 g, 34.49 mmol) and K3PO4 (12.20 g, 57.48 mmol) were combined in MeCN (100 mL)/Water (25 mL) and Pd[P(tBu)3]2 (734.4 mg, 1.437 mmol) was added. The reaction was heated at 60° C. for 1 hour. The reaction mixture was cooled to ambient temperature and diluted with EtOAc and water. The layers were separated and the aqueous layer extracted with EtOAc (×3). The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was triturated from DCM and isolated by filtration to give the sub-title compound as an orange solid (6.43 g, 76% Yield). 1H NMR (400.0 MHz, DMSO) δ 1.17 (d, 6H), 3.43 (sept, 1H), 6.86 (s, 2H), 7.87 (d, 2H), 8.00 (s, 1H), 8.20 (d, 2H) and 8.67 (s, 1H) ppm; MS (ES+) 278.2.
5-(4-(Isopropylsulfonyl)phenyl)pyrazin-2-amine (10 g, 36.06 mmol) was dissolved in dry DMF (70 mL) and N-bromosuccinimide (6.418 g, 36.06 mmol) was added portionwise. The mixture was stirred at ambient temperature for 2 hours. The reaction mixture was poured into water (200 mL) and stirred for 5 minutes. The solid was isolated by filtration and washed with water. The wet solid was dissolved in ethyl acetate and any insoluble material removed by filtration. The aqueous layer was separated and the organic phase washed with saturated aqueous Na2S2O3 (×1) and dried (MgSO4). The organic extracts were filtered through a plug of Florisil (200 mesh), eluting with ethyl acetate. The filtrate was concentrated to ca. 50 mL and resultant precipitate isolated by filtration and washed with Petroleum Ether. The solid was further dried under high vacuum to give the sub-title compound as a pale orange solid (8.0 g, 62% Yield).). 1H NMR (400.0 MHz, DMSO) δ 1.17 (d, 6H), 3.41-3.49 (m, 1H), 7.16 (br s, 2H), 7.89 (d, 2H), 8.17 (d, 2H) and 8.76 (s, 1H) ppm; MS (ES+) 356.1.
Triethylamine (47.58 g, 65.54 mL, 470.2 mmol) was added to a stirred suspension of 3-bromo-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine (33.5 g, 94.04 mmol) in anhydrous DMF (234.5 mL). Copper(I) iodide (2.148 g, 11.28 mmol) was then added followed by Pd(PPh3)4 (5.433 g, 4.702 mmol). The stirred mixture was cooled to 0° C. in an ice-bath and (trimethylsilyl)acetylene (12.01 g, 17.28 mL, 122.3 mmol) was added dropwise over 10 minutes. The ice bath was then removed and the mixture allowed to warm to ambient temperature over 2 hours. The mixture was poured into EtOAc/water (500 mL/300 mL) and the mixture was filtered through a pad of celite. The organic phase was separated and the aqueous layer extracted with EtOAc. The combined organics were washed with water (×1) and brine (×1), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by column chromatography (ISCO Companion™, 750 g column, eluting with 0 to 15% DCM/EtOAc, dry-loaded) to give the sub-title product as a dark yellow solid (28.0 g, 78% Yield). 1H NMR (400.0 MHz, DMSO) δ 0.15 (s, 9H, 1.03 (d, 6H), 3.29 (sept, 1H), 6.80 (br s, 2H), 7.74 (d, 2H), 8.05 (d, 2H) and 8.60 (s, 1H) ppm; MS (ES+) 375.1.
Triethylamine (18.42 g, 25.37 mL, 182.0 mmol) was added to a stirred solution of 5-(4-isopropylsulfonylphenyl)-3-(2-trimethylsilylethynyl)pyrazin-2-amine (34 g, 91.02 mmol) in DCM (1.020 L). DMAP (1.112 g, 9.102 mmol) was added followed by tert-butoxycarbonyl tert-butyl carbonate (59.60 g, 62.74 mL, 273.1 mmol) in portions. The reaction mixture was stirred at ambient temperature for 16 hours. The reaction mixture was poured into water (500 mL) and the organic layer separated. The organic layer was washed with brine (×1), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 20-30% EtOAc/Petroleum Ether to give the sub-title product as an orange foam (42.6 g, 82% Yield). 1H NMR (400.0 MHz, CDCl3) δ 0.15 (s, 9H), 1.19 (d, 6H), 1.28 (s, 18H), 3.10 (sept, 1H), 7.89 (d, 2H), 8.12 (d, 2H) and 8.75 (s, 1H) ppm; MS (ES+) 574.1.
tert-Butyl N-tert-butoxycarbonyl-N-[5-(4-isopropylsulfonylphenyl)-3-(2-trimethylsilyl ethynyl)pyrazin-2-yl]carbamate (42.6 g, 74.25 mmol) was dissolved/suspended in methanol (510 mL) and 2M aqueous sodium carbonate (425.8 mL, 851.6 mmol) was added to the rapidly stirred mixture. An oil separated out and more methanol (100 mL) was added to dissolve. The mixture was stirred at ambient temperature for 1 hour. The slurry was poured into a mixture of EtOAc/water (800 mL/1 L). The organic phase was separated and the aqueous extracted with EtOAc (2×250 mL). The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was slurried in 5% EtOAc/Petroleum Ether and stirred for 90 minutes at ambient temperature. The precipitate was isolated by filtration, washed with Petroleum Ether and dried to give the sub-title product as a white solid (33.1 g, 89% Yield). 1H NMR (400.0 MHz, DMSO) δ 1.18 (d, 6H), 1.37 (s, 18H), 3.50 (sept, 1H), 4.99 (s, 1H), 8.03 (d, 2H), 8.44 (d, 2H) and 9.35 (s, 1H) ppm; MS (ES+) 502.1.
TFA (34.45 g, 23.28 mL, 302.1 mmol) was added to a stirred solution of tert-butyl N-tert-butoxycarbonyl-N-[3-ethynyl-5-(4-isopropylsulfonylphenyl)pyrazin-2-yl]carbamate (5 g, 9.968 mmol) in DCM (200 mL) and the reaction mixture stirred at ambient temperature for 1.5 hours. The solvent was removed in vacuo and the residue re-dissolved in DCM and stirred with saturated aqueous NaHCO3 for 30 minutes. The layers were separated and the organic layer washed with saturated aqueous NaHCO3 (×3). The combined aqueous layers were extracted with DCM (×3) and the combined organic extracts dried (MgSO4), filtered and concentrated in vacuo. The residue was triturated from DCM and precipitate isolated by filtration and dried under vacuum to give the title product as a beige solid (2.8 g, 93% Yield). 1H NMR (400.0 MHz, DMSO) δ 1.18 (d, 6H), 3.44 (t, 1H), 4.76 (s, 1H), 7.01 (s, 2H), 7.89 (d, 2H), 8.20 (d, 2H) and 8.75 (s, 1H) ppm; MS (ES+) 302.12.
KOtBu (2.041 g, 18.19 mmol) in anhydrous NMP (5 mL) was stirred at 80° C. while a solution of 3-ethynyl-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine (2.7685 g, 9.095 mmol) in dry NMP (15 mL) was added slowly over 5 minutes. The resultant solution was stirred at 80° C. for 1.5 hours. The reaction mixture was cooled to ambient temperature and the solvent concentrated in vacuo. The residue was diluted with EtOAc and washed with water (×6). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give the sub-title compounds as a beige solid (1.88 g, 69% Yield). 1H NMR (400.0 MHz, DMSO) δ H NMR (400.0 MHz, DMSO) δ 1.20 (d, 6H), 3.49 (sept, 1H), 6.74 (dd, 1H), 7.96-8.00 (m, 3H), 8.43 (d, 2H), 9.00 (s, 1H) and 12.25 (s, 1H) ppm; MS (ES+) 302.1.
2-(4-Isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazine (1 g, 3.318 mmol) was dissolved in anhydrous pyridine (20 mL) and cooled to 0° C. in an ice-bath. 1M ICl in DCM (3.484 mL, 3.484 mmol) was added slowly and the resultant solution stirred at 0° C. After 5 hours a further portion of 1M ICl in DCM (3.484 mL, 3.484 mmol) was added and the reaction allowed to warm to ambient temperature over 16 hours. A further portion of 1M ICl in DCM (3.484 mL, 3.484 mmol) was added and the reaction stirred at ambient temperature for a further 30 minutes. The reaction mixture was concentrated in vacuo and the residue partitioned between EtOAc and saturated aqueous Na2CO3/saturated aqueous Na2S2O3 (1:1). The aqueous layer was extracted with EtOAc (100 mL) and the combined organic extracts washed with saturated aqueous Na2CO3/saturated aqueous Na2S2O3 (1:1) (5×50 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was triturated from MeCN to give the sub-title compound as a pale orange solid (1.23 g, 87% Yield). 1H NMR (400.0 MHz, DMSO) δ 1.21 (d, 6H), 3.49 (s, 1H), 8.01 (d, 2H), 8.22 (s, 1H), 8.46 (d, 2H), 9.03 (s, 1H) and 12.71 (s, 1H) ppm; MS (ES+) 428.0.
A 60% dispersion of sodium hydride in mineral oil (130.2 mg, 3.398 mmol) was added slowly to a stirred solution of 7-iodo-2-(4-isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazine (1.21 g, 2.832 mmol) in DMF (10 mL) at 0° C. The reaction mixture was stirred at this temperature for 20 minutes then tosyl chloride (539.9 mg, 2.832 mmol) was added and reaction mixture allowed to warm to ambient temperature over 16 hours. The reaction mixture was quenched by the slow addition of water (30 mL) and the mixture stirred for 20 minutes. The resultant precipitate was isolated by filtration, washed with water and dried under vacuum to give the sub-title product as a yellow solid (1.52 g, 92% Yield). 1H NMR (400.0 MHz, DMSO) δ 1.22-1.19 (m, 6H), 2.36 (s, 3H), 3.50-3.45 (m, 1H), 7.48 (d, 2H), 8.05 (q, 4H), 8.42 (d, 2H), 8.64 (s, 1H), and 9.18 (s, 1H) ppm; MS (ES+) 581.9.
CuI (95 mg, 0.4988 mmol), and N,N′-dimethylethane-1,2-diamine (175 mg, 1.985 mmol) in dioxane (30 mL) was heated for 5 minutes at 100° C. in a microwave. 1 mL of this solution was added to a mixture of 7-iodo-2-(4-isopropylsulfonylphenyl)-5-(p-tolylsulfonyl)pyrrolo[2,3-b]pyrazine (100 mg, 0.1720 mmol), isoindolin-1-one (114.5 mg, 0.8600 mmol) in dioxane (7.35 mL) and the solution was heated at 95° C. for 30 minutes before addition of K3PO4 was added and the mixture was heated for 20 min at 95° C. The reaction mixture was concentrated in vacuo. The residue was partitioned between DCM and water. Combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo yielding an oil which was purified by prep HPLC to give the sub-title product (12 mg, 16%).). 1H NMR (400.0 MHz, DMSO) δ 1.20 (6H, d), 3.50 (1H, sep), 5.53 (2H, s), 7.59 (1H, t), 7.72 (1H, t), 7.78 (2H, m), 7.97 (2H, d), 8.52 (3H, m), 9.08 (1H, s), 12.44 (1H, brs) ppm; MS (ES+) 441.10.
The following compounds were prepared using procedures analogous to that described above in Example 1:
1H NMR (400.0 MHz, DMSO) δ12.33 (d, J=2.7 Hz, 1H), 9.05 (s, 1H), 8.44 (d, J=8.5 Hz, 2H), 8.25 (d, J=2.9 Hz, 1H), 8.00-7.95 (m, 3H), 7.57 (s, 1H), 7.42 (d, J=7.5 Hz, 2H), 4.37-4.34 (m, 2H), 3.46 (qt, J=6.9 Hz, 1H), 3.25 (t, J=6.5 Hz, 2H) and 1.19 (d, J=6.8 Hz, 6H) ppm; MS (ES+) 447.0.
1H NMR (400 MHz, DMSO) δ1.20 (6H, d), 1.49 (3H, d), 3.48 (1H, sep), 5.90 (1H, q), 7.59 (1H, t), 7.74 (1H, dd), 7.82 (2H, t), 7.97 (2H, d), 8.37 (1H, s), 8.45 (2H, d), 9.08 (1H, s), 12.44 (1H, brs) ppm; MS (ES+) 447.0.
Triethyl(ethynyl)silane (6.102 g, 7.793 mL, 43.49 mmol) followed by triethylamine (5.201 g, 7.164 mL, 51.40 mmol) was added to a thoroughly degassed suspension of 3,5-dibromopyrazin-2-amine (10 g, 39.54 mmol), copper(I) iodide (753.0 mg, 3.954 mmol) and Pd(PPh3)2Cl2 (2.775 g, 3.954 mmol) in tetrahydrofuran (200.0 mL) and the resulting solution stirred at ambient temperature over 18 hours. (On addition reaction mixture changes colour rapidly from yellow to orange to red to dark red and brown and then orange). Reaction mixture is cooled to ambient temperature and then diluted with EtOAc and 10% solution of NH4OH (100 mL) added and the layers separated. EtOAc layer washed once more with 10% NH4OH. Aqueous layer extracted further with EtOAc (×3) and combined organics dried over (MgSO4), filtered and concentrated in vacuo to a brown oil. Purified on Companion using a 330 g pre-packed silica column loading with DCM and eluting with 0-100% Petrol/DCM. Relevant fractions combined and concentrated in vacuo to give a brown oil (11.24 g, 91%). 1H NMR (400.0 MHz, DMSO) δ 0.67-0.74 (m, 6H), 0.99-1.03 (m, 9H), 6.72 (s, 2H) and 8.14 (s, 1H) ppm; MS (ES+) 314.06.
Potassium tert-butoxide (6.612 g, 58.92 mmol) was suspended/dissolved in dry N-methylpyrrolidinone (15 mL) and stirred at 80° C. while a solution of 5-bromo-3-(2-triethylsilylethynyl)pyrazin-2-amine (9.1992 g, 29.46 mmol) in dry N-methylpyrrolidinone (50 mL) was added slowly drop wise over 10 minutes. The dropping funnel was washed out with a further aliquot of dry N-methylpyrrolidinone (10 mL). The resultant was stirred at 80° C. for 1.5 hours. Reaction mixture cooled to ambient then diluted with EtOAc and water and EtOAc layer washed with small portions of water (×6). Organic layer dried (MgSO4), filtered and concentrated in vacuo to give a dark brown solid (4.1 g, 70.3%). 1H NMR (400.0 MHz, DMSO) δ 12.50 (s, 1H), 8.37 (s, 1H), 8.01 (s, 1H) and 6.64 (q, J=1.7 Hz, 1H) ppm; MS (ES+) 198.10.
2-bromo-5H-pyrrolo[2,3-b]pyrazine (20 g, 101.0 mmol) was dissolved in ice-cold sulfuric acid (140.0 mL), producing a bright orange solution, and concentrated nitric acid (12.73 g, 8.470 mL, 202.0 mmol) was added drop wise with stirring over 30 min keeping the temperature under 10° C. (turning the solution to a clear red colour). The reaction was removed from the ice bath after 30 min and allowed to warm to ambient temperature and left to stir at ambient temperature for 1 hour. The reaction mixture was poured onto ice to obtain a yellow solid. The solid was filtered, washed with water to give 2-bromo-7-nitro-5H-pyrrolo[2,3-b]pyrazine the desired product as a yellow solid. (21.76 g, 88.7%). MS (ES+) 244.87.
2-bromo-7-nitro-5H-pyrrolo[2,3-b]pyrazine (5 g, 20.57 mmol) was dissolved in DMF (100 mL) under N2. Solution was cooled in an ice bath and sodium hydride (867.1 mg, 22.63 mmol) added portionwise. After 30 minutes (effervescence completed) trityl chloride (6.022 g, 21.60 mmol) was added in one portion and the mixture allowed to warm to ambient temperature (Precipitate observed after around 15 mins). Reaction mixture was poured into water and mixture stirred for 1 hour then filtered. Solid was washed with copious water then dried in a vacuum oven over 48 hours at 80° C. Taken on to the next step as is. (9.7 g, 97.3%) 1H NMR (400.0 MHz, DMSO) δ 8.46 (s, 1H), 8.40 (s, 1H), 7.38-7.36 (m, H), 7.23-7.20 (m, 8H) and 3.32 (s, 7H) ppm
2-bromo-7-nitro-5-trityl-pyrrolo[2,3-b]pyrazine (5 g, 10.30 mmol) dissolved in tetrahydrofuran (200.0 mL)/water (50.00 mL) and indium (11.83 g, 103.0 mmol) then HCl (20.60 mL of 6 M, 123.6 mmol) added. Indium dissolves then precipitates out over 5 minutes. Reaction mixture is filtered through celite, washing with EtOAc. Filtrate basified by careful addition of NaHCO3. Emulsion forms and mixture is filtered again before layers separated. Aqueous is extracted with EtOAc. Combined organics dried and concentrated in vacuo to a black foam. Residue is taken up in DCM and purified by chromatography eluting with 0-50% EtOAc—petroleum ether). Product obtained as a green/brown foam. Dried on high vacuum and taken directly on to acylation reaction. (3.43 g, 73%). 1H NMR (400.0 MHz, DMSO) δ 8.46 (s, 1H), 8.40 (s, 1H), 7.38-7.36 (m, H), 7.23-7.20 (m, 8H) and 3.32 (s, 7H) ppm; MS (ES+) 457.0
2-bromo-5-trityl-pyrrolo[2,3-b]pyrazin-7-amine (3 g, 6.588 mmol) dissolved in THF (30 mL) under N2 at rt. DIPEA (5.7 mL, 32.9 mmol) added followed by a solution of 2-(bromomethyl)benzoyl chloride (1.9 g, 8.137 mmol) in THF (10 mL). Reaction mixture stirred overnight then partitioned between EtOAc and water. Aqueous phase extracted with EtOAc. Combined organics washed with saturated NaHCO3 solution then brine, dried and concentrated. Residue taken up in DCM and purified by chromatography (0-40% EtOAc-petroleum ether gradient). Further purification by chromatography (isocratic DCM elution) gives the title compound as a yellow foam (1.45 g, 34%); 1H NMR (400 MHz, DMSO) δ 4.93 (2H, s), 7.21-7.38 (15H, m), 7.44-7.61 (3H, m), 7.62 (1H, d), 8.19 (1H, s), 8.59 (1H, s), 10.93 (1H, s) ppm; MS (ES+) 653.0.
2-(bromomethyl)-N-(2-bromo-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl)benzamide (1.45 g, 2.223 mmol) dissolved in DMF (20 mL) under N2 and solution cooled in an ice bath. NaH (60% w/w suspension in mineral oil, 89.43 mg, 2.334 mmol) added in two portions and the reaction mixture stirred with cooling. After 2 h, an additional ˜20 mg NaH added. After a further 30 mins, reaction quenched by careful addition of water. The resulting yellow precipitate collected by filtration, washing with water. Precipitate dried at 50° C. in vacuuo to give title compound as a pale yellow solid (1.17 g, 92%); 1H NMR (400 MHz, DMSO) δ 5.37 (2H, s), 7.20-7.22 (5H, m), 7.30-7.39 (10H, m), 7.54 (1H, t), 7.68 (1H, t), 7.74 (1H, d), 7.79 (1H, d), 8.23 (1H, s), 8.59 (1H, s) ppm; MS (ES+) 571.0.
2-(2-bromo-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl)isoindolin-1-one (20 mg, 0.3500 mmol), [4-(dimethylcarbamoyl)phenyl]boronic acid (81.06 mg, 0.4200 mmol) and Na2CO3 (525.0 μL of a 2M aqueous solution, 1.050 mmol) combined in 1,4-dioxane (3 mL) and the mixture de-gassed (×2 vacuum-N2 cycles). Pd(tBu3P)2 (17.89 mg, 0.03500 mmol) added and the mixture de-gassed (×2 cycles) then heated at 65° C. overnight. Reaction mixture cooled to ambient and partitioned between DCM and water. Aqueous phase extracted with DCM and combined organics dried and concentrated to a yellow solid, which is taken up in DCM (4 mL) under N2 and used in the next step without further purification.
Et3SiH (279.5 μL, 1.750 mmol) then TFA (1 mL) added to N,N-dimethyl-4-(7-(1-oxoisoindolin-2-yl)-5-trityl-5H-pyrrolo[2,3-b]pyrazin-2-yl)benzamide. Reaction was stirred overnight then concentrated. Residue azeotroped with DCM (×3) then taken up in DMSO and purified by hplc to give the title compound as a white solid (51 mg, 37% over two steps); 1H NMR (400 MHz, DMSO) δ 2.99 (3H, partly obsc s), 3.02 (3H, partly obsc s), 5.52 (2H, s), 7.56-7.61 (3H, m), 7.70 (1H, t), 7.80-7.85 (2H, m), 8.28 (2H, d), 8.48 (1H, s), 9.01 (1H, s), 12.25 (1H, brs) ppm; MS (ES+) 398.0.
The following compounds were prepared using procedures analogous to that described above in Example 2:
1H NMR (400 MHz, DMSO) δ 4.71-4.77 (4H, m), 4.92 (1H, qn), 5.47 (2H, s), 7.54 (1H, t), 7.67 (1H, t), 7.74 (1H, d), 7.79 (1H, d), 8.01 (2H, d), 8.46-8.48 (3H, m), 9.03 (1H, s), 12.30 (1H, brs) ppm; MS (ES+) 447.0.
1H NMR (400 MHz, DMSO) 1.82 (6H, s), 5.57 (2H, s), 7.58 (1H, t), 7.69-7.76 (2H, m), 7.83 (1H, d), 8.25 (1H, d), 8.46 (1H, s), 8.55 (1H, s), 8.75 (1H, d), 9.18 (1H, s), 12.42 (1H, vbrs) ppm; MS (ES+) 395.0.
1H NMR (400 MHz, DMSO) δ 1.24-1.30 (2H, m), 1.37-1.44 (1H, m), 1.73-1.82 (1H, m), 2.08-2.14 (1H, m), 2.67-2.77 (3H, m), 2.93 (2H, t), 4.23 (1H, d), 5.55 (1H, d) 5.62 (1H, d), 7.58 (1H, dt), 7.70-7.76 (2H, m), 7.84 (1H, d), 8.28 (1H, dd), 8.53 (1H, s), 8.82 (1H, d), 9.23 (1H, s), 12.41 (1H, brs) ppm; MS (ES+) 462.0.
1H NMR (400 MHz, DMSO) δ 1.28-1.35 (1H, m), 1.48 (1H, dq), 1.64-1.67 (1H, m), 1.99-2.02 (1H, m), 2.28-2.34 (1H, m), 2.82 (1H, brd), 3.12 (1H, brd), 3.24 (1H, tt), 5.53 (2H, s), 7.59 (1H, t), 7.72 (1H, t), 7.81 (1H, overlapping d), 7.83 (1H, overlapping d), 7.98 (2H, d), 8.51-8.54 (3H, m), 9.10 (1H, s), 12.37 (1H, brs) ppm; MS (ES+) 474.0.
Compounds of formula I may also be made by reacting the aminopyrrolopyrazine of formula C with an isobenzofuranone under suitable conditions, such as in the presence of AlMe3 in heptanes and toluene, form the compound of formula C-i. The protecting group PG′ can be removed under standard conditions known to those skilled in the art such as, but not limited to, treatment with aqueous base or TBAF when PG′ is tosyl (p-toluenesulfonyl) or hydrogenation when PG′ is a trityl group to give compounds of Formula I.
2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-amine (332 mg, 0.5942 mmol) dissolved in PhMe (5 mL) and AlMe3 in heptane (1.783 mL of 1.0 M, 1.783 mmol) added at RT under N2. After 30 minutes, a solution of 5-bromo-3H-isobenzofuran-1-one (253 mg, 1.188 mmol) in DCM (5 mL) added with cooling in an ice bath. RM stirred overnight, temperature rising to ambient. RM re-cooled in an ice bath and water (3 mL) added slowly. After 5 minutes, RM diluted with DCM. Resulting mixture filtered to remove bulk of Al salts. Brine added and the layers separated. Aqueous extracted with DCM (×2). Combined organics dried and concentrated to a brown foam (514 mg). This material dissolved in THF (6 mL) under N2 and PPh3 (233.8 mg, 0.8913 mmol) then DEAD (112 μL, 0.7130 mmol) added. Mixture stirred overnight at RT. RM concentrated and residue partitioned between DCM and brine. Aqueous phase extracted with DCM and combined extracts dried and concentrated. Residue treated with 1:1 DCM:MeOH and resulting pale yellow solid collected by filtration and dried under vacuum to give title compound (293 mg, 65%); 1H NMR (400 MHz, DMSO) δ 0.98 (6H, d), 3.28 (1H, sep), 5.40 (2H, s), 5.55 (2H, s), 7.05-7.18 (15H, m), 7.48 (1H, d), 7.55 (1H, dd), 7.74 (2H, d), 7.87 (1H, s), 8.28 (2H, d), 8.39 (1H, s), 8.67 (1H, s); MS (ES+) 754.0.
5-bromo-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (50 mg, 0.06634 mmol) suspended in DCM (2 mL) under N2 and triethylsilane (53 μL, 0.3317 mmol) then TFA (300 μL, 3.894 mmol) added. RM stirred overnight then concentrated. Residue partitioned between DCM and saturated NaHCO3 solution. Organic phase washed with brine then dried and concentrated to a yellow solid. Dried at 60° C. in a vacuum oven to give title compound as a pale yellow solid (17 mg, 49%); 1H NMR (400 MHz, DMSO) δ1.22 (6H, d), 3.50 (1H, sep), 5.54 (2H, s), 7.77 (2H, s), 7.99 (2H, d), 8.08 (1H, s), 8.51-8.55 (3H, m), 9.11 (1H, s), 12.36 (1H, brs) ppm; MS (ES+) 512.0.
The following compounds were prepared using procedures analogous to that described above in Example 3:
1H NMR (400 MHz, DMSO) δ 1.01 (6H, d), 3.30 (1H, sep), 5.41 (2H, s), 7.78-7.85 (4H, m), 8.12 (1H, s), 8.31-8.35 (3H, m), 8.91 (1H, s), 12.22 (1H, s) ppm; MS (ES+) 458.0.
1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.51 (1H, sep), 5.52 (2H, s), 7.65 (1H, t), 7.81 (1H, dd), 8.02 (1H, d), 8.48-8.52 (3H, m), 9.11 (1H, s), 12.40 (1H, s) ppm; MS (ES+) 467.0
1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.50 (1H, sep), 5.51 (2H, s), 7.58 (1H, d), 7.69 (1H, t), 7.77 (1H, d), 8.00 (2H, d), 8.53 (2H, d), 9.10 (1H, s), 12.37 (1H, s); MS (ES+) 467.0.
1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.49 (1H, sep), 5.65 (2H, s), 7.99-8.04 (3H, m), 8.17 (1H, d), 8.30 (1H, s), 8.53 (3H, m), 9.11 (1H, s), 12.40 (1H, s) ppm; MS (ES+) 458.0.
1H NMR (400 MHz, DMSO) δ 1.28 (6H, d), 3.57 (1H, sep), 5.70 (2H, s), 7.98 (1H, t), 8.04-8.07 (3H, m), 8.16 (1H, d), 8.60 (2H, d), 9.17 (1H, s), 12.48 (1H, s) ppm; MS (ES+) 478.0.
5-bromo-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (100 mg, 0.1327 mmol), 1H-pyrazol-5-ylboronic acid (17.81 mg, 0.1592 mmol) and Na2CO3 (200 μL of 2 M aqueous solution, 0.40 mmol) combined in 1,4-dioxane (1.5 mL). Mixture de-gassed (×3 vacuum-N2 cycles). Pd(tBu3P)2 (6.782 mg, 0.01327 mmol) added and mixture de-gassed (×3 cycles) then heated overnight at 60° C. Reaction mixture partitioned between DCM and water. Aqueous phase extracted with DCM. Combined organics dried and concentrated. Residue taken up in DCM (2 mL) and Et3SiH (106.0 μL, 0.6635 mmol) then TFA (0.3 mL) added under N2. Mixture stirred for 48 h then concentrated and residue azeotroped with DCM (×3). Residue purified by hplc to give the title compound (14 mg, 21%); 1H NMR (400 MHz, DMSO) 1.22 (6H, d), 3.50 (1H, sep), 5.58 (2H, s), 6.90 (1H, d), 7.83-7.87 (2H, m), 8.00 (2H, d), 8.05 (1H, d), 8.25 (1H, s), 8.53-8.57 (3H, m), 9.11 (1H, s), 12.33 (1H, vbrs), 13.10 (1H, s); MS (ES+) 499.0.
Some of the above compounds were transformed further prior to deprotection to provide the following compounds:
2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]-1-oxo-isoindoline-5-carbonitrile (111 mg, 0.1586 mmol) dissolved in a mixture of DCM (10 mL) and MeOH (5 mL) under N2. CoCl2 (41.18 mg, 0.3172 mmol) added and resulting green solution cooled in an ice bath. NaBH4 (60 mg, 1.586 mmol) added in one portion and the ice bath removed. After 2 h reaction re-cooled in an ice bath and water (˜5 mL) added. Mixture diluted with DCM (˜20 mL) and stirred vigorously for 20 mins. Layers separated and aqueous extracted with DCM. Aqueous phase basified by addition of sat NaHCO3 solution and extracted with DCM (×2). Combined organics dried and concentrated to give the title compound as a yellow solid 88% pure by UV (112 mg, 82%); MS (ES+) 704.0.
5-(aminomethyl)-2-(2-(4-(isopropylsulfonyl)phenyl)-5-trityl-5H-pyrrolo[2,3-b]pyrazin-7-yl)isoindolin-1-one deprotected using Method E Step 2 to give the title compound after purification by hplc; 1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.50 (1H, sep), 3.90 (2H, s), 5.50 (2H, s), 7.54 (1H, d), 7.76 (2H, d), 8.00 (2H, d), 8.51-8.54 (3H, m), 9.09 (1H, s) ppm; MS (ES+) 462.0.
4-chloro-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (95 mg, 0.1339 mmol) dissolved in 1,4-dioxane (2 mL) and Zn(CN)2 (17.30 mg, 0.1473 mmol) then Pd(tBu3P)2 (6.843 mg, 0.01339 mmol) added. Mixture de-gassed (×3 vacuum-N2 cycles) then heated at 100° C. for 2 h. A further 10 mg ZnCN2 and 10 mg Pd(tBu3P)2 added and heating continued at 115° C. overnight. Reaction mixture cooled and partitioned between DCM and brine. Aqueous phase extracted with DCM and combined organics dried and concentrated. Residue treated with DCM and MeOH (˜1:1) and resulting cloudy solution concentrated to a tan solid consisting of a mixture of title compound [MS (ES+) 700.0] and H-de-Cl starting material. This mixture used directly in further transformations.
2-(2-(4-(isopropylsulfonyl)phenyl)-5-trityl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-1-oxoisoindoline-4-carbonitrile deprotected using Method E Step 2 to give the title compound after purification by hplc; MS (ES+) 458.0.
2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]-1-oxo-isoindoline-4-carbonitrile (80 mg, 0.1143 mmol) dissolved in DCM (10 mL) and MeOH (5 mL) under N2. CoCl2 (29.68 mg, 0.2286 mmol) added and the reaction mixture cooled in an ice bath. NaBH4 (43 mg, 1.143 mmol) added in one portion. Ice bath removed and mixture stirred for 2 h then cooled in an ice bath and water (˜5 mL) added. Mixture diluted with DCM (˜20 mL) and stirred vigorously for 20 mins. Layers separated and aqueous phase extracted with DCM. Aqueous phase basified by addition of sat NaHCO3 solution and extracted with DCM (×2). Combined organics dried and concentrated to a brown foam. This material deprotected using Method E Step 2 to give the title compound after purification by hplc; 1H NMR (400 MHz, DMSO) δ 1.21 (6H, s), 3.50 (1H, sep), 4.03 (2H, s), 5.59 (2H, s), 7.56 (1H, t), 7.71 (2H, m), 8.01 (2H, d), 8.51 (1H, s), 8.54 (2H, d), 9.12 (1H, s) ppm; MS (ES+) 462.0.
7-chloro-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (153 mg, 0.2157 mmol) dissolved in 1,4-dioxane (2 mL) and Zn(CN)2 (27.87 mg, 0.2373 mmol) then Pd(tBu3P)2 (11.02 mg, 0.02157 mmol) added. Mixture de-gassed (×3 vacuum-N2 cycles), then heated at 100° C. for 2 h. A further 10 mg ZnCN2 and 10 mg Pd(tBu3P)2 added and heating continued at 115° C. overnight. Reaction mixture cooled and partitioned between DCM and brine. Aqueous phase extracted with DCM and combined organics dried and concentrated. Residue treated with DCM and MeOH (˜1:1) and resulting cloudy solution concentrated. Resulting pale green solid used directly in further reactions.
2-(2-(4-(isopropylsulfonyl)phenyl)-5-trityl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-3-oxoisoindoline-4-carbonitrile deprotected using Method E Step 2 to give the title compound after purification by hplc. Isolated as TFA salt; 1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.50 (1H, sep), 5.61 (2H, s), 7.89 (1H, t), 8.00 (2H, d), 8.05 (1H, d), 8.14 (1H, d), 8.51-8.55 (2H, m), 8.60 (1H, d), 9.11 (1H, s), 12.42 (1H, s) ppm; MS (ES+) 458.0.
2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]-3-oxo-isoindoline-4-carbonitrile (150 mg, 0.2143 mmol) dissolved in a mixture of DCM (10 mL) and MeOH (5 mL) under N2. CoCl2 (55.65 mg, 0.4286 mmol) added then the reaction mixture cooled in an ice bath. NaBH4 (81 mg, 2.143 mmol) added in one portion. Ice bath removed and mixture stirred for 3 h then cooled in an ice bath and water (˜5 mL) added. Mixture diluted with DCM (˜20 mL) and stirred vigorously for 20 mins. Layers separated and aqueous extracted with DCM. Aqueous phase basified by addition of sat NaHCO3 solution and extracted with DCM (×2). Combined organics dried and concentrated to a black foam. This material deprotected using Method E Step 2 to give the title compound after purification by hplc; 1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.50 (1H, sep), 4.17 (2H, s), 5.50 (2H, s), 7.51-7.53 (1H, m), 7.62-7.65 (3H, m), 8.00 (2H, d), 8.51-8.54 (3H, m), m 9.09 (1H, s) ppm; MS (ES+) 462.0.
2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]-3-oxo-isoindoline-5-carbonitrile (130 mg, 0.1858 mmol) dissolved in a mixture of DCM (10 mL) and MeOH (5 mL) under N2. CoCl2 (48.25 mg, 0.3716 mmol) added then the reaction mixture cooled in an ice bath. NaBH4 (70 mg, 1.858 mmol) added in one portion. Ice bath removed and mixture stirred for 2 h then cooled in an ice bath and water (˜5 mL) added. Mixture diluted with DCM (˜20 mL) and stirred vigorously for 20 mins. Layers separated and aqueous extracted with DCM. Aqueous phase basified by addition of sat NaHCO3 solution and extracted with DCM (×2). Combined organics dried and concentrated to a brown foam. This material deprotected using Method E Step 2 to give the title compound after purification by hplc; 1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.50 (1H, sep), 3.88 (2H, s), 5.49 (2H, s), 7.65 (1H, d), 7.71 (1H, d), 7.84 (1H, s), 8.00 (2H, d), 8.51-8.53 (3H, m), 9.09 (1H, s) ppm; MS (ES+) 462.0.
2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]-7-nitro-isoindolin-1-one (148 mg, 0.2056 mmol) suspended in EtOH (5 mL) and mixture heated to 70° C. SnCl2.2H2O (232.0 mg, 1.028 mmol) added and the mixture heated at reflux. After 1 h a further ˜200 mg SnCl2.2H2O added. After 1 h reaction mixture cooled, diluted with DCM and sat NaHCO3 added. Mixture stirred vigorously for 30 mins then passed through a phase separator cartridge. Org phase concentrated to a yellow solid (158 mg). This material deprotected using Method E Step 2 to give the title compound after purification using hplc; 1H NMR (400 MHz, DMSO) δ 1.21 (6H, d), 3.49 (1H, sep), 5.35 (2H, s), 6.22 (2H, s), 6.65 (1H, d), 6.81 (1H, d), 7.31 (1H, dd), 7.99 (2H, d), 8.43 (1H, s), 8.50 (2H, d), 9.07 (1H, s), 12.27 (1H, brs) ppm; MS (ES+) 448.0.
7-amino-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (63 mg, 0.09133 mmol) dissolved in DCE (5 mL) and acetaldehyde (5.6 μL, 0.10 mmol) then Na(OAc)3BH (38.72 mg, 0.1827 mmol) added at RT under N2. Reaction mixture stirred for 48 h then quenched by the addition of water. DCM added and layers separated. Organic phase dried and concentrated. Residue taken up in DCM (2 mL) under N2 and treated with triethylsilane (73 μL, 0.4566 mmol) then TFA (300 μL). Reaction mixture stirred overnight then concentrated. Residue purified by hplc to give the title compound; 1H NMR (400 MHz, DMSO) δ 1.20-1.26 (9H, m), 3.50 (1H, partly obsc sep), 5.38 (2H, s), 6.64-6.68 (2H, m), 6.85 (1H, d), 7.42 (1H, d), 8.00 (2H, d), 8.44 (1H, d), 8.51 (2H, d), 9.08 (1H, s), 12.31 (1H, s) ppm; MS (ES+) 476.0.
7-amino-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one obtained above from synthesis of compound I-21 prior to deprotection (63 mg, 0.091 mmol) dissolved in DCE (5 mL). Formaldehyde (18.53 μL of 37% w/v aqueous solution, 0.2283 mmol) then Na(OAc)3BH (58.07 mg, 0.2740 mmol) added at RT under N2 and the reaction mixture stirred for 48 h. A further 2 eq formaldehyde and 2 eq Na(OAc)3BH added and the mixture stirred overnight at 50° C. Reaction then heated to 80° C. for 3 h, cooled to ambient and quenched by the addition of water. Mixture diluted with DCM. Layers separated and organic phase dried and concentrated. Residue taken up in DCM (2 mL) and triethylsilane (73 μL, 0.4566 mmol) then TFA (300 μL) added under N2. Reaction mixture stirred overnight then concentrated. Residue taken up in DMSO, filtered and purified by hplc. Mono and bis-methylated products isolated;
1H NMR (400 MHz, DMSO) 1.21 (6H, d), 2.90 (3H, d), 3.50 (1H, sep), 5.38 (2H, s), 6.60 (1H, d), 6.72 (1H, br q), 6.85 (1H, d), 7.44 (1H, t), 7.99 (2H, d), 8.42 (1H, s), 8.51 (2H, d), 9.08 (1H, s), 12.30 (1H, s); MS (ES+) 462.0;
1H NMR (400 MHz, DMSO) 1.21 (6H, d), 2.99 (6H, s), 3.50 (1H, partly obsc sep), 5.42 (2H, s), 6.97 (1H, d), 7.20 (1H, d), 7.52 (1H, t), 8.00 (2H, d), 8.50 (1H, d), 8.52 (2H, d), 9.08 (1H, s), 12.30 (1H, d); MS (ES+) 476.0.
In some instances further synthetic steps are required for synthesis of the lactone, for example:
3-(2-hydroxyethyl)-3H-isobenzofuran-1-one (1.03 g, 5.781 mmol) dissolved in THF (10 mL) under N2 and TBDMSCl (958.4 mg, 6.359 mmol) then imidazole (472.3 mg, 6.937 mmol) added at RT. Reaction mixture stirred overnight then concentrated. Residue partitioned between EtOAc and water. Aqueous phase extracted with EtOAc and combined organics dried and concentrated. Residue purified by chromatography (silica, 0-100% EtOAc-petrol gradient elution). Title compound obtained as a colourless oil (1.47 g, 87%), 1H NMR (400 MHz, DMSO) 0.00 (3H, s), 0.01 (3H, s), 0.83 (9H, s), 1.76-1.85 (1H, m), 2.23-2.31 (1H, s), 3.71-3.80 (2H, m), 5.66 (1H, dd), 7.57 (1H, t), 7.68 (1H, d), 7.75 (1H, dt), 7.81 (1H, d); MS (ES+) 293.0.
2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-amine (125 mg, 0.2237 mmol) dissolved in PhMe (3 mL) under N2. AlMe3 in heptane (671.1 μL of 1.0 M, 0.6711 mmol) added at RT and the mixture stirred for 30 mins. A solution of 3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-3H-isobenzofuran-1-one (130.8 mg, 0.4474 mmol) in DCM (3 mL) added with cooling on an ice bath and the mixture stirred overnight. Reaction mixture re-cooled and water added slowly followed by DCM. After stirring for 30 mins, mixture passed through a phase separator cartridge and filtrate concentrated. Residue taken up in THF (5 mL) and PPh3 (88.02 mg, 0.3356 mmol) then DEAD (42.26 μL, 0.2684 mmol) added at RT under N2. Reaction mixture stirred overnight, then concentrated without heating. Residue partitioned between DCM and brine. Aqueous phase extracted with DCM and combined organics dried and concentrated. Residue taken up in DCM and purified by chromatography (silica, 0-100% EtOAc-petrol gradient elution) to give the title compound as a yellow foam (123 mg, 66% over 2 steps); MS (ES+) 833.3.
3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (123 mg, 0.1476 mmol) dissolved in THF (2 mL) under N2. TBAF in THF (442.8 μL of 1.0 M, 0.4428 mmol) in THF added and the mixture stirred for 90 mins. Reaction mixture partitioned between DCM and brine. Aqueous phase extracted with DCM and combined organics dried and concentrated. Residue purified by chromatography (silica, 0-100% EtOAc-petrol gradient). Title compound obtained as a yellow film, (87 mg, 82%), taken on directly to deprotection reaction; MS (ES+) 719.0.
3-(2-hydroxyethyl)-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (58 mg, 0.08068 mmol) dissolved in DCM (2 mL) under N2 and Et3SiH (64.44 μL, 0.4034 mmol) then TFA (300 μL) added. Reaction mixture stirred overnight, then concentrated and residue azeotroped with DCM (×3). Purified by hplc to give the title compound as a pale yellow solid (19.3 mg, 50%); 1H NMR (400 MHz, DMSO) 1.03 (6H, d), 1.72-1.79 (1H, m), 2.00-2.15 (1H, m), 3.00-3.09 (1H, m), 3.32 (1H, sep), 4.28 (1H, t), 5.82-5.85 (1H, m), 7.42 (1H, t), 7.57 (1H, t), 7.65 (2H, d), 7.80 (2H, d), 8.21 (1H, s), 8.32 (2H, d), 8.93 (1H, s), 12.30 (1H, brs); MS (ES+) 477.0.
Compounds of formula I may also be made by reacting the aminopyrrolopyrazine of formula C-0 with an isobenzofuranone under suitable conditions, such as in the presence of AlMe3 in heptanes and toluene, form the compound of formula C-ii. These compounds of C-li are functionalised using a range of known metal mediated reactions such as, but not limited to, Sonogashira couplings, Negishi couplings, Suzuki couplings, and Stille couplings to give compounds of Formula C-iii. The protecting group PG′ can be removed under standard conditions known to those skilled in the art such as, but not limited to, treatment with aqueous base or TBAF when PG′ is tosyl (p-toluenesulfonyl) or hydrogenation when PG′ is a trityl group to give compounds of Formula I.
2-bromo-5-trityl-pyrrolo[2,3-b]pyrazin-7-amine (4.82 g, 10.59 mmol) suspended in PhMe (72 mL) and AlMe3 in heptane (31 mL of 1.0 M, 31 mmol) added at RT under N2. After 30 minutes, a solution of 7-chloro-3H-isobenzofuran-1-one (3.570 g, 21.18 mmol) in DCM (72 mL) added with cooling on an ice bath. Reaction mixture stirred overnight, temperature rising to ambient. Reaction mixture re-cooled on an ice bath and water (˜30 mL) added slowly. After 5 minutes mixture diluted with DCM. Resulting mixture stirred vigorously for 30 mins then filtered through celite to remove bulk of Al salts. Layers separated. Aqueous extracted with DCM (×2). Combined organics dried and concentrated to a brown solid. This material dissolved in THF (200 mL) under N2 and Ph3P (4.165 g, 15.88 mmol) then DEAD (2.00 mL, 12.71 mmol) added. Reaction mixture stirred overnight at RT then concentrated. Residue partitioned between DCM and brine. Aqueous phase extracted with DCM and combined organics dried and concentrated. Resulting black residue taken up in DCM. Some product precipitates and is collected by filtration. Filtrate purified by chromatography (silica, 0-5% MeOH-DCM gradient elution). Product fractions concentrated to a brown solid and further purified by trituration with DCM/MeOH (˜1:1) to give a yellow solid. Combined product dried under vacuum at 60° C. to give the title compound as a yellow solid (2.39 g, 37% over two steps); 1H NMR (400 MHz, DMSO) δ 5.85 (2H, s), 7.76-7.84 (15H, m), 7.97 (1H, d), 8.12 (1H, t), 8.21 (1H, d), 8.54 (1H, s), 9.22 (1H, s) ppm; MS (ES+) 606.0.
2-(2-bromo-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl)-7-chloro-isoindolin-1-one (150 mg, 0.2476 mmol), tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonylpiperidine-1-carboxylate (112 mg, 0.2476 mmol) and Na2CO3 (371 μL of a 2.0 M aqueous solution, 0.7428 mmol) combined in 1,4-dioxane (3 mL) under N2. Mixture de-gassed (×3 vacuum-N2 cycles) then Pd(PPh3)4 (14 mg, 0.01238 mmol) added. Reaction mixture de-gassed (×3 cycles) and stirred overnight at 110° C. Reaction cooled and partitioned between DCM and water. Aqueous phase extracted with DCM and combined organics dried and concentrated. Residue purified by chromatography (silica, 0-100% EtOAc-petroleum ether gradient elution). Title compound obtained as a yellow solid (186 mg, 88%), taken directly on to deprotection reaction; MS (ES+) 850.0.
tert-butyl 4-[4-[7-(7-chloro-1-oxo-isoindolin-2-yl)-5-trityl-pyrrolo[2,3-b]pyrazin-2-yl]phenyl]sulfonylpiperidine-1-carboxylate (186 mg, 0.2187 mmol) dissolved in DCM (2 mL) and triethylsilane (175 μL, 1.094 mmol) then TFA (0.3 mL) added under N2. Reaction mixture stirred overnight and residue azeotroped with DCM (×2) then purified by hplc. Product isolated as the TFA salt (80 mg, 59%); 1H NMR (400 MHz, DMSO) δ 1.72 (2H, brdq), 2.08 (2H, brd), 2.89 (2H, brq), 3.37 (2H, partly obsc brd), 3.63-3.70 (1H, partly obsc m), 5.49 (2H, s), 7.59 (1H, d), 7.70 (1H, t), 7.74 (1H, t), 7.99 (2H, d), 8.10-8.26 (1H, m), 8.55-8.58 (4H, m), 9.11 (1H, s), 12.42 (1H, d) ppm; MS (ES+) 508.0.
The following compound was prepared using procedures analogous to that described above in Example 4:
1H NMR (400 MHz, DMSO) δ 1.60-1.67 (2H, m), 1.90-1.94 (1H, m), 2.08 (1H, brs), 2.88-3.04 (2H, m), 3.22 (1H, brd), 3.48 (1H, partly obsc brd), 3.59-3.63 (1H, partly obsc m), 5.50 (2H, s), 7.59 (1§H, d), 7.70 (1H, partly obsc t), 7.74 (1H, partly obsc t), 8.02 (2H, d), 8.36 (1H, vbrd), 8.55 (1H, d), 8.59 (2H, d), 8.91 (1H, vbrd), 9.13 (1H, s), 12.43 (1H, brs) ppm; MS (ES+) 508.0.
X is halogen and —NRaRb is R1 bonded via a nitrogen atom
To a reaction tube charged with and Cs2CO3 (97 mg, 0.3 mmol) was added a stock solution of 6-iodo-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (120 mg, 0.15 mmol), Pd(OAc)2 (3.4 mg, 0.015 mmol) and Xantphos (17 mg, 0.03 mmol) in 1,4-dioxane (1 mL). The tube was flushed with N2 and then heated to 100° C. overnight. After this time PS-isocyanate resin was added and the solution left for 1 hour before being filtered and washed with 1,4-dioxane. The dioxane was blown off to give a brown residue, which was re-dissolved in DCM (10 mL) and TFA (2 mL) then Et3SiH added. This was left overnight before being passed crude down an SXCX-2 cartridge, washing with MeOH/MeCN and then eluting the compounds off with MeOH/NH3 in MeCN. Purification by hplc gave the title compound as a yellow solid; 1H NMR (400.0 MHz, DMSO) δ 12.36 (d, J=2.8 Hz, 1H), 9.09 (s, 1H), 8.52-8.50 (m, 3H), 8.12 (s, 2H), 8.00 (d, J=8.5 Hz, 2H), 7.61 (d, J=8.3 Hz, 1H), 6.96 (dd, J=2.2, 8.4 Hz, 1H), 6.90 (d, J=2.1 Hz, 1H), 5.40 (s, 2H), 4.02 (s, 1H), 3.65-3.47 (m, 5H), 2.37 (t, J=7.0 Hz, 1H), 2.12-2.08 (m, 1H) and 1.21 (d, J=6.8 Hz, 6H) ppm; MS (ES+) 517.2.
The following compounds were prepared using procedures analogous to that described above in Example 5:
1H NMR (400.0 MHz, DMSO) δ 12.35 (d, J=2.8 Hz, 1H), 9.43 (s, 1H), 9.09 (s, 1H), 8.52-8.49 (m, 3H), 8.01-7.99 (m, 2H), 7.52 (d, J=8.2 Hz, 1H), 7.04-6.99 (m, 2H), 5.36 (s, 2H), 3.50 (t, J=6.8 Hz, 2H), 3.28 (t, J=6.3 Hz, 2H), 2.86 (s, 6H) and 1.21 (d, J=6.7 Hz, 6H) ppm; MS (ES+) 519.1.
1H NMR (400.0 MHz, DMSO) δ 12.28 (s, 1H), 9.02 (s, 1H), 8.44 (d, J=8.4 Hz, 3H), 8.01 (s, 2H), 7.93 (d, J=8.5 Hz, 2H), 7.54 (d, J=8.4 Hz, 1H), 6.84 (d, J=2.1 Hz, 2H), 5.33 (s, 2H), 3.95 (m, 1H), 3.45 (m, 5H), 2.25 (m, 1H), 2.13 (m, 1H) and 1.14 (d, J=6.8 Hz, 6H) ppm; MS (ES+) 517.1.
1H NMR (400.0 MHz, DMSO) δ 12.25 (s, 1H), 9.07 (s, 1H), 8.51 (d, J=8.3 Hz, 2H), 8.45 (s, 1H), 8.00 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.6 Hz, 1H), 7.24 (s, 1H), 7.10 (d, J=8.3 Hz, 1H), 5.41 (s, 2H), 3.49 (d, J=6.9 Hz, 1H), 3.27 (d, J=4.5 Hz, 4H), 2.88-2.86 (m, 4H), 2.77 (s, 1H) and 1.22 (d, J=6.8 Hz, 6H) ppm; MS (ES+) 517.1.
MS (ES+) 531.3
MS (ES+) 531.1
1H NMR (400.0 MHz, DMSO) δ 12.27 (d, J=2.8 Hz, 1H), 9.08 (d, J=5.9 Hz, 1H), 8.52-8.46 (m, 4H), 8.01-7.99 (m, 2H), 7.62 (d, J=8.6 Hz, 1H), 7.16 (d, J=1.7 Hz, 1H), 7.03 (dd, J=2.1, 8.7 Hz, 1H), 5.44-5.41 (m, 2H), 4.22 (s, 1H), 3.83 (s, 1H), 3.64 (d, J=11.5 Hz, 1H), 3.51 (qn, J=6.8 Hz, 1H), 3.41 (d, J=12.0 Hz, 2H), 3.11 (d, J=10.4 Hz, 2H), 2.86 (s, 3H), 1.95 (d, J=13.1 Hz, 1H), 1.84 (d, J=12.3 Hz, 1H) and 1.21 (d, J=6.7 Hz, 6H) ppm; MS (ES+) 545.1
MS (ES+) 561.1
MS (ES+) 545.1
MS (ES+) 491.4
MS (ES+) 531.1
MS (ES+) 547.2
MS (ES+) 559.2
MS (ES+) 531.1
MS (ES+) 503.1
1H NMR (400.0 MHz, DMSO) δ 12.27 (d, J=2.8 Hz, 1H), 9.07 (s, 1H), 8.65 (m, 1H), 8.50 (d, J=8.5 Hz, 2H), 8.44 (d, J=2.8 Hz, 1H), 7.99 (d, J=8.5 Hz, 2H), 7.55 (d, J=8.4 Hz, 1H), 6.88 (s, 1H), 6.79 (dd, J=1.8, 8.4 Hz, 1H), 6.55 (s, 1H), 5.38 (s, 2H), 3.72 (s, 1H), 3.50 (qn, J=6.8 Hz, 1H), 3.42 (d, J=10.7 Hz, 1H), 3.27 (d, J=13.0 Hz, 1H), 3.25 (m, 1H), 2.89 (m, 1H), 2.03 (m, 1H), 1.93 (m, 1H), 1.71 (m, 1H), 1.56 (m, 1H) and 1.21 (d, J=6.8 Hz, 6H) ppm MS (ES+) 531.2
MS (ES+) 517.1
MS (ES+) 517.1
To a 5 mL reaction vial was added 6-iodo-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (100 mg, 0.1250 mmol), copper (3.972 mg, 0.06250 mmol), CuI (23.81 mg, 0.1250 mmol) and K3PO4 (53.07 mg, 0.2500 mmol). To this was added 2-dimethylaminoethanol (1 mL) and the vial capped and heated to 135° C. and stirred overnight. LCMS showed reaction had gone to completion. Water was added and the aqueous extracted with DCM (10 mL).
To the DCM layer was added TFA (2 mL) and Et3SiH (72.67 mg, 99.82 μL, 0.6250 mmol) and the resulting solution stirred for 2 h. After this time the reaction mixture was conc. in vacuo and the residue redissolved in DMSO and purified by reverse phase HPLC to give 6-[2-(dimethylamino)ethoxy]-2-[2-(4-isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (17.9 mg, 0.03376 mmol, 27.01%) H NMR (400.0 MHz, DMSO) δ 12.39 (d, 1H), 9.10 (s, 1H), 8.52 (dd, 2H), 8.52 (s, 1H), 8.00 (d, 2H), 7.75 (d, 1H), 7.44 (d, 1H), 7.35 (dd, 1H), 5.47 (s, 2H), 4.48-4.46 (m, 2H), 3.58 (t, 2H), 3.50 (t, 1H), 2.91 (d, 6H) and 1.21 (d, 6H) ppm ESI-MS m/z calc. 519.19403. found 520.5 (M+1)+. Retention time: 0.8 minutes.
To a microwave vial containing copper (4.216 mg, 0.06635 mmol), 5-bromo-2-[2-(4-isopropylsulfonylphenyl)-5-trityl-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (100 mg, 0.1327 mmol), CuI (25.27 mg, 0.1327 mmol) and K3PO4 (56.34 mg, 0.2654 mmol) was added 2-dimethylaminoethanol (1.000 mL). The resulting suspension was heated to 125° C. for 3 h. After this time DCM and water were added and the organic layer separated, dried (MgSO4) and concentrated.
The residue was dissolved in DCM (5 mL) and TFA (5 mL) followed by addition of Et3SiH (77.15 mg, 106.0 μL, 0.6635 mmol). The mixture was stirred overnight, and then passed through an SCX cartridge eluting with MeOH, followed by MeOH:NH3, concentrated, redissolved in DMSO and purified by reverse phase HPLC to give 5-[2-(dimethylamino)ethoxy]-2-[2-(4-isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]isoindolin-1-one (29.47 mg, 0.05388 mmol, 40.60%) H NMR (400.0 MHz, DMSO) δ 12.35 (d, 1H), 9.75 (s, 1H), 9.09 (s, 1H), 8.52-8.48 (m, 3H), 8.00 (d, 2H), 7.79 (d, 1H), 7.44 (d, 1H), 7.19 (dd, 1H), 5.49 (s, 2H), 4.49-4.46 (m, 2H), 3.60 (d, 2H), 3.50 (t, 1H), 2.91 (d, 6H) and 1.21 (d, J=6.8 Hz, 6H) ppm ESI-MS m/z calc. 519.19403. found 520.2 (M+1)+. Retention time: 0.78 minutes
Compounds can be screened for their ability to inhibit intracellular ATR using an immunofluorescence microscopy assay to detect phosphorylation of the ATR substrate histone H2AX in hydroxyurea treated cells. HT29 cells are plated at 14,000 cells per well in 96-well black imaging plates (BD 353219) in McCoy's 5A media (Sigma M8403) supplemented with 10% foetal bovine serum (JRH Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100 (Sigma P7539), and 2 mM L-glumtamine (Sigma G7513), and allowed to adhere overnight at 37° C. in 5% CO2. Compounds are then added to the cell media from a final concentration of 25 μM in 3-fold serial dilutions and the cells are incubated at 37° C. in 5% CO2. After 15 min, hydroxyurea (Sigma H8627) is added to a final concentration of 2 mM.
After 45 min of treatment with hydroxyurea, the cells are washed in PBS, fixed for 10 min in 4% formaldehyde diluted in PBS (Polysciences Inc 18814), washed in 0.2% Tween-20 in PBS (wash buffer), and permeabilised for 10 min in 0.5% Triton X-100 in PBS, all at room temperature. The cells are then washed once in wash buffer and blocked for 30 min at room temperature in 10% goat serum (Sigma G9023) diluted in wash buffer (block buffer). To detect H2AX phosphorylation levels, the cells are then incubated for 1 h at room temperature in primary antibody (mouse monoclonal anti-phosphorylated histone H2AX Ser139 antibody; Upstate 05-636) diluted 1:250 in block buffer. The cells are then washed five times in wash buffer before incubation for 1 h at room temperature in the dark in a mixture of secondary antibody (goat anti-mouse Alexa Fluor 488 conjugated antibody; Invitrogen A11029) and Hoechst stain (Invitrogen H3570); diluted 1:500 and 1:5000, respectively, in wash buffer. The cells are then washed five times in wash buffer and finally 100 ul PBS is added to each well before imaging.
Cells are imaged for Alexa Fluor 488 and Hoechst intensity using the BD Pathway 855 Bioimager and Attovision software (BD Biosciences, Version 1.6/855) to quantify phosphorylated H2AX Ser139 and DNA staining, respectively. The percentage of phosphorylated H2AX-positive nuclei in a montage of 9 images at 20× magnification is then calculated for each well using BD Image Data Explorer software (BD Biosciences Version 2.2.15). Phosphorylated H2AX-positive nuclei are defined as Hoechst-positive regions of interest containing Alexa Fluor 488 intensity at 1.75-fold the average Alexa Fluor 488 intensity in cells not treated with hydroxyurea. The percentage of H2AX positive nuclei is finally plotted against concentration for each compound and IC50s for intracellular ATR inhibition are determined using Prism software (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).
The compounds described herein can also be tested according to other methods known in the art (see Sarkaria et al, “Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine: Cancer Research 59: 4375-5382 (1999); Hickson et al, “Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM” Cancer Research 64: 9152-9159 (2004); Kim et al, “Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members” The Journal of Biological Chemistry, 274(53): 37538-37543 (1999); and Chiang et al, “Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family” Methods Mol. Biol. 281:125-41 (2004)).
Compounds were screened for their ability to inhibit ATR kinase using a radioactive-phosphate incorporation assay. Assays were carried out in a mixture of 50 mM Tris/HCl (pH 7.5), 10 mM MgCl2 and 1 mM DTT. Final substrate concentrations were 10 μM [γ-33P]ATP (3mCi 33P ATP/mmol ATP, Perkin Elmer) and 800 μM target peptide (ASELPASQPQPFSAKKK) (SEQ. ID. NO: 1).
Assays were carried out at 25° C. in the presence of 5 nM full-length ATR. An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 13.5 μL of the stock solution was placed in a 96 well plate followed by addition of 2 μL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 15 μM with 3-fold serial dilutions) in duplicate (final DMSO concentration 7%). The plate was pre-incubated for 10 minutes at 25° C. and the reaction initiated by addition of 15 μL [γ-33P]ATP (final concentration 10 μM).
The reaction was stopped after 24 hours by the addition of 30 μL 0.1M phosphoric acid containing 2 mM ATP. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHN0B50) was pretreated with 100 μL 0.2M phosphoric acid prior to the addition of 45 μL of the stopped assay mixture. The plate was washed with 5×200 μL 0.2M phosphoric acid. After drying, 100 μL Optiphase ‘SuperMix’ liquid scintillation cocktail (Perkin Elmer) was added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).
After removing mean background values for all of the data points, Ki(app) data were calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).
Below is a chart showing the ATR Inhibition Ki values of compounds of the disclosure. Compounds with a Ki value of ≦50 nM are marked with “+++.” Compounds with a Ki value ≦100 nM but ≧50 nM are marked with “++.” Compounds with a Ki value >100 nM but <250 nM are marked with “+.”
Compounds can be screened for their ability to sensitize HCT116 colorectal cancer cells to Cisplatin using a 96 h cell viability (MTS) assay. HCT116 cells, which possess a defect in ATM signaling to Cisplatin (see, Kim et al.; Oncogene 21:3864 (2002); see also, Takemura et al.; JBC 281:30814 (2006)) are plated at 470 cells per well in 96-well polystyrene plates (Costar 3596) in 150 μl of McCoy's 5A media (Sigma M8403) supplemented with 10% foetal bovine serum (JRH Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100 (Sigma P7539), and 2 mM L-glumtamine (Sigma G7513), and allowed to adhere overnight at 37° C. in 5% CO2. Compounds and Cisplatin are then both added simultaneously to the cell media in 2-fold serial dilutions from a top final concentration of 10 μM as a full matrix of concentrations in a final cell volume of 200 μl, and the cells are then incubated at 37° C. in 5% CO2. After 96 h, 40 μl of MTS reagent (Promega G358a) is added to each well and the cells are incubated for 1 h at 37° C. in 5% CO2. Finally, absorbance is measured at 490 nm using a SpectraMax Plus 384 reader (Molecular Devices) and the concentration of compound required to reduce the IC50 of Cisplatin alone by at least 3-fold (to 1 decimal place) can be reported either with an IC50 or Ki value.
While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds, methods, and processes of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example herein.
This present application claims the benefit, under 35 U.S.C. §119, to U.S. Provisional Application No. 61/500,113, filed Jun. 22, 2011; U.S. Provisional Application No. 61/510,200, filed Jul. 21, 2011; and U.S. Provisional Application No. 61/620,697, filed Apr. 5, 2012, the entire contents of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4309430 | Bock et al. | Jan 1982 | A |
| 5143824 | Yamakawa et al. | Sep 1992 | A |
| 6060478 | Gilligan et al. | May 2000 | A |
| 6191131 | He et al. | Feb 2001 | B1 |
| 6235741 | Bilodeau et al. | May 2001 | B1 |
| 6660753 | Van Wagenen et al. | Dec 2003 | B2 |
| 6858600 | Hamilton et al. | Feb 2005 | B2 |
| 6992087 | Verhoest et al. | Jan 2006 | B2 |
| 7041672 | Verhoest et al. | May 2006 | B2 |
| 7199123 | Munchhof | Apr 2007 | B2 |
| 7452993 | Arnold et al. | Nov 2008 | B2 |
| 7528138 | Knegtel et al. | May 2009 | B2 |
| 7550470 | Fraley | Jun 2009 | B2 |
| 7622583 | Ungashe et al. | Nov 2009 | B2 |
| 7626021 | Arnold et al. | Dec 2009 | B2 |
| 7700601 | Chan et al. | Apr 2010 | B2 |
| 7704995 | Buhr et al. | Apr 2010 | B2 |
| 7829558 | Arnold et al. | Nov 2010 | B2 |
| 7872031 | Lauffer et al. | Jan 2011 | B2 |
| 7902197 | Elworthy et al. | Mar 2011 | B2 |
| 7932254 | Dubois et al. | Apr 2011 | B2 |
| 7939531 | Bamberg et al. | May 2011 | B2 |
| 7981893 | Mortensen et al. | Jul 2011 | B2 |
| 8063032 | Chytil et al. | Nov 2011 | B2 |
| 8106197 | Cui et al. | Jan 2012 | B2 |
| 8410112 | Charrier et al. | Apr 2013 | B2 |
| 8492582 | Yokotani et al. | Jul 2013 | B2 |
| 8623869 | Charrier et al. | Jan 2014 | B2 |
| 8822469 | MacCormick et al. | Sep 2014 | B2 |
| 8957078 | Brenchley et al. | Feb 2015 | B2 |
| 8962631 | Charrier et al. | Feb 2015 | B2 |
| 8969360 | Charrier et al. | Mar 2015 | B2 |
| 9096602 | Everitt et al. | Aug 2015 | B2 |
| 20020041880 | DeFeo-Jones et al. | Apr 2002 | A1 |
| 20030008882 | Hamilton et al. | Jan 2003 | A1 |
| 20030055085 | Wagenen et al. | Mar 2003 | A1 |
| 20040034037 | Harbeson et al. | Feb 2004 | A1 |
| 20040180905 | Munchhof | Sep 2004 | A1 |
| 20060156482 | Lim | Jul 2006 | A1 |
| 20060211709 | Buhr et al. | Sep 2006 | A1 |
| 20070037794 | Ungashe et al. | Feb 2007 | A1 |
| 20070254868 | Lauffer et al. | Nov 2007 | A1 |
| 20070270420 | Harbeson et al. | Nov 2007 | A1 |
| 20070287711 | Arnold et al. | Dec 2007 | A1 |
| 20090005381 | Brown et al. | Jan 2009 | A1 |
| 20090215724 | Dubois et al. | Aug 2009 | A1 |
| 20090215750 | Bamberg et al. | Aug 2009 | A1 |
| 20090215785 | DuBois et al. | Aug 2009 | A1 |
| 20090215788 | Elworthy et al. | Aug 2009 | A1 |
| 20090306087 | Ibrahim et al. | Dec 2009 | A1 |
| 20090318436 | Albrecht et al. | Dec 2009 | A1 |
| 20100036118 | Arnold et al. | Feb 2010 | A1 |
| 20100168138 | DeGoey et al. | Jul 2010 | A1 |
| 20100204214 | Chytil et al. | Aug 2010 | A1 |
| 20100222318 | Charrier et al. | Sep 2010 | A1 |
| 20100233091 | Neumann et al. | Sep 2010 | A1 |
| 20110015231 | Al-Abed et al. | Jan 2011 | A1 |
| 20110275797 | Yokotani et al. | Nov 2011 | A1 |
| 20110288067 | Hendricks et al. | Nov 2011 | A1 |
| 20110288097 | Hendricks et al. | Nov 2011 | A1 |
| 20120027874 | Charrier et al. | Feb 2012 | A1 |
| 20120035407 | Charrier et al. | Feb 2012 | A1 |
| 20120035408 | Charrier et al. | Feb 2012 | A1 |
| 20120040020 | Charrier et al. | Feb 2012 | A1 |
| 20120046295 | Charrier et al. | Feb 2012 | A1 |
| 20120065247 | Thompson et al. | Mar 2012 | A1 |
| 20120115874 | Wang et al. | May 2012 | A1 |
| 20120122884 | Charrier et al. | May 2012 | A1 |
| 20120177748 | Charrier et al. | Jul 2012 | A1 |
| 20120178756 | Charrier et al. | Jul 2012 | A1 |
| 20130017273 | Everitt et al. | Jan 2013 | A1 |
| 20130018035 | MacCormick et al. | Jan 2013 | A1 |
| 20130034616 | Storck et al. | Feb 2013 | A1 |
| 20130089624 | Charrier et al. | Apr 2013 | A1 |
| 20130089625 | Charrier et al. | Apr 2013 | A1 |
| 20130089626 | Pollard et al. | Apr 2013 | A1 |
| 20130095193 | Charrier et al. | Apr 2013 | A1 |
| 20130096139 | Charrier et al. | Apr 2013 | A1 |
| 20130115310 | Charrier et al. | May 2013 | A1 |
| 20130115311 | Charrier et al. | May 2013 | A1 |
| 20130115312 | Charrier et al. | May 2013 | A1 |
| 20130115313 | Charrier et al. | May 2013 | A1 |
| 20130115314 | Charrier et al. | May 2013 | A1 |
| 20130172273 | Aizpurua Iparraguirre et al. | Jul 2013 | A1 |
| 20130184292 | Charrier et al. | Jul 2013 | A1 |
| 20140113005 | Charrier et al. | Apr 2014 | A1 |
| 20140163000 | Ahmad et al. | Jun 2014 | A1 |
| 20140249157 | Ahmad et al. | Sep 2014 | A1 |
| 20140275009 | Brenchley et al. | Sep 2014 | A1 |
| 20140275021 | Charrier et al. | Sep 2014 | A1 |
| 20140275130 | Charrier et al. | Sep 2014 | A1 |
| 20140288347 | Charrier et al. | Sep 2014 | A1 |
| 20150158868 | Boyall et al. | Jun 2015 | A1 |
| 20150158872 | Charrier et al. | Jun 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 101537007 | Sep 2009 | CN |
| 101671336 | Mar 2010 | CN |
| 103373996 | Oct 2013 | CN |
| 313724 | May 1989 | EP |
| 1217000 | Jun 2002 | EP |
| 2157090 | Feb 2010 | EP |
| 2001-302666 | Oct 2001 | JP |
| WO 9635690 | Nov 1996 | WO |
| 9743267 | Nov 1997 | WO |
| WO 9803510 | Jan 1998 | WO |
| WO 9833799 | Aug 1998 | WO |
| 9842701 | Oct 1998 | WO |
| WO 9854093 | Dec 1998 | WO |
| 0004014 | Jan 2000 | WO |
| WO 0053605 | Sep 2000 | WO |
| 01044206 | Jun 2001 | WO |
| WO 0140231 | Jun 2001 | WO |
| WO 0192257 | Dec 2001 | WO |
| WO 0240485 | May 2002 | WO |
| WO 02066481 | Aug 2002 | WO |
| 03004472 | Jan 2003 | WO |
| 03004475 | Jan 2003 | WO |
| WO 03000187 | Jan 2003 | WO |
| WO 03037900 | May 2003 | WO |
| 03045924 | Jun 2003 | WO |
| 03076422 | Sep 2003 | WO |
| 03080610 | Oct 2003 | WO |
| 03087057 | Oct 2003 | WO |
| 03092686 | Nov 2003 | WO |
| 03093297 | Nov 2003 | WO |
| 03101968 | Dec 2003 | WO |
| 2004000318 | Dec 2003 | WO |
| WO 03101993 | Dec 2003 | WO |
| WO 2004022559 | Mar 2004 | WO |
| WO 2004022560 | Mar 2004 | WO |
| WO 2004022561 | Mar 2004 | WO |
| 2004033431 | Apr 2004 | WO |
| WO 2004026229 | Apr 2004 | WO |
| WO 2004052315 | Jun 2004 | WO |
| 2004055005 | Jul 2004 | WO |
| 2004055006 | Jul 2004 | WO |
| 2004080982 | Sep 2004 | WO |
| WO 2004076458 | Sep 2004 | WO |
| 2004084813 | Oct 2004 | WO |
| 2004084824 | Oct 2004 | WO |
| 2004085409 | Oct 2004 | WO |
| 2004103279 | Dec 2004 | WO |
| 2005028475 | Mar 2005 | WO |
| WO 2005028434 | Mar 2005 | WO |
| WO 2005051906 | Jun 2005 | WO |
| WO 2005054246 | Jun 2005 | WO |
| WO 2005077954 | Aug 2005 | WO |
| 2005079802 | Sep 2005 | WO |
| WO 2005080396 | Sep 2005 | WO |
| 2005123672 | Dec 2005 | WO |
| WO 2005117909 | Dec 2005 | WO |
| 2006015124 | Feb 2006 | WO |
| 2006053342 | May 2006 | WO |
| WO 2006052913 | May 2006 | WO |
| 2006058074 | Jun 2006 | WO |
| 2006067462 | Jun 2006 | WO |
| 2006071548 | Jul 2006 | WO |
| 2006075152 | Jul 2006 | WO |
| WO 2006071752 | Jul 2006 | WO |
| 2006088837 | Aug 2006 | WO |
| WO 2006087120 | Aug 2006 | WO |
| 2006114180 | Nov 2006 | WO |
| 2006120573 | Nov 2006 | WO |
| WO 2006128184 | Nov 2006 | WO |
| 0209648 | Feb 2007 | WO |
| 2007015632 | Feb 2007 | WO |
| WO 2007041712 | Apr 2007 | WO |
| WO 2007044401 | Apr 2007 | WO |
| WO 2007044407 | Apr 2007 | WO |
| WO 2007044410 | Apr 2007 | WO |
| WO 2007044420 | Apr 2007 | WO |
| WO 2007044426 | Apr 2007 | WO |
| WO 2007044441 | Apr 2007 | WO |
| WO 2007044449 | Apr 2007 | WO |
| WO 2007046548 | Apr 2007 | WO |
| WO 2007048066 | Apr 2007 | WO |
| 2007058850 | May 2007 | WO |
| 2007063012 | Jun 2007 | WO |
| 2007066805 | Jun 2007 | WO |
| 2007076360 | Jul 2007 | WO |
| 2007096151 | Aug 2007 | WO |
| 2007096764 | Aug 2007 | WO |
| 2007096765 | Aug 2007 | WO |
| 2007102770 | Sep 2007 | WO |
| 2007111904 | Oct 2007 | WO |
| 2007126964 | Nov 2007 | WO |
| WO 2007126841 | Nov 2007 | WO |
| 2007147874 | Dec 2007 | WO |
| WO 2007139732 | Dec 2007 | WO |
| WO 2007139856 | Dec 2007 | WO |
| WO 2007139860 | Dec 2007 | WO |
| WO 2008004698 | Jan 2008 | WO |
| WO 2008008539 | Jan 2008 | WO |
| 2008037477 | Apr 2008 | WO |
| 2008038010 | Apr 2008 | WO |
| 2008040651 | Apr 2008 | WO |
| WO 2008045266 | Apr 2008 | WO |
| WO 2008045268 | Apr 2008 | WO |
| 2008060907 | May 2008 | WO |
| WO 2008063671 | May 2008 | WO |
| 2008071456 | Jun 2008 | WO |
| 2008074997 | Jun 2008 | WO |
| 2008079291 | Jul 2008 | WO |
| 2008079903 | Jul 2008 | WO |
| 2008079906 | Jul 2008 | WO |
| 2008103277 | Aug 2008 | WO |
| 2008106692 | Sep 2008 | WO |
| 2008122375 | Oct 2008 | WO |
| 2008124850 | Oct 2008 | WO |
| WO 2008130569 | Oct 2008 | WO |
| WO 2008130570 | Oct 2008 | WO |
| 2008141065 | Nov 2008 | WO |
| 2008144463 | Nov 2008 | WO |
| 2008144464 | Nov 2008 | WO |
| 2008157191 | Dec 2008 | WO |
| WO 2008151735 | Dec 2008 | WO |
| 2009007390 | Jan 2009 | WO |
| 2009012482 | Jan 2009 | WO |
| 2009014637 | Jan 2009 | WO |
| WO 2009006580 | Jan 2009 | WO |
| 2009016460 | Feb 2009 | WO |
| 2009024825 | Feb 2009 | WO |
| WO 2009017954 | Feb 2009 | WO |
| 2009037247 | Mar 2009 | WO |
| 2009053737 | Apr 2009 | WO |
| WO 2009070567 | Jun 2009 | WO |
| WO 2009075790 | Jun 2009 | WO |
| WO 2009088986 | Jul 2009 | WO |
| WO 2009091374 | Jul 2009 | WO |
| WO 2009095254 | Aug 2009 | WO |
| 2009106885 | Sep 2009 | WO |
| WO 2009117157 | Sep 2009 | WO |
| WO 2010002483 | Jan 2010 | WO |
| WO 2010006086 | Jan 2010 | WO |
| 2010015803 | Feb 2010 | WO |
| WO 2010017047 | Feb 2010 | WO |
| 2010048131 | Apr 2010 | WO |
| WO 2010034738 | Apr 2010 | WO |
| 2010054398 | May 2010 | WO |
| WO 2010051549 | May 2010 | WO |
| WO 2010059836 | May 2010 | WO |
| 2010063634 | Jun 2010 | WO |
| 2010068483 | Jun 2010 | WO |
| 2010071837 | Jun 2010 | WO |
| WO 2010086040 | Aug 2010 | WO |
| WO 2010091409 | Aug 2010 | WO |
| 2011008830 | Jan 2011 | WO |
| WO 2011003065 | Jan 2011 | WO |
| WO 2011022439 | Feb 2011 | WO |
| WO 2011068667 | Jun 2011 | WO |
| 2011117145 | Sep 2011 | WO |
| WO 2011113606 | Sep 2011 | WO |
| 2011124998 | Oct 2011 | WO |
| 2011130689 | Oct 2011 | WO |
| WO 2011121096 | Oct 2011 | WO |
| 2011143399 | Nov 2011 | WO |
| 2011143419 | Nov 2011 | WO |
| 2011143422 | Nov 2011 | WO |
| 2011143423 | Nov 2011 | WO |
| 2011143425 | Nov 2011 | WO |
| 2011143426 | Nov 2011 | WO |
| 2011144584 | Nov 2011 | WO |
| 2011144585 | Nov 2011 | WO |
| WO 2011163518 | Dec 2011 | WO |
| WO 2012007375 | Jan 2012 | WO |
| WO 2012022045 | Feb 2012 | WO |
| WO 2012027236 | Mar 2012 | WO |
| WO 2012067822 | May 2012 | WO |
| WO 2012078855 | Jun 2012 | WO |
| WO 2012100342 | Aug 2012 | WO |
| WO 2012138938 | Oct 2012 | WO |
| WO 2012143510 | Oct 2012 | WO |
| WO 2012143796 | Oct 2012 | WO |
| 2012158785 | Nov 2012 | WO |
| WO 2012177997 | Dec 2012 | WO |
| WO 2012178124 | Dec 2012 | WO |
| WO 2013010136 | Jan 2013 | WO |
| 2013049726 | Apr 2013 | WO |
| WO 2013052263 | Apr 2013 | WO |
| WO 2013138436 | Sep 2013 | WO |
| WO 2013151930 | Oct 2013 | WO |
| WO 2013151938 | Oct 2013 | WO |
| WO 2013154878 | Oct 2013 | WO |
| WO 2013174930 | Nov 2013 | WO |
| WO 2013174931 | Nov 2013 | WO |
| WO 2014011911 | Jan 2014 | WO |
| WO 2014015523 | Jan 2014 | WO |
| WO 2014023691 | Feb 2014 | WO |
| WO 2014025850 | Feb 2014 | WO |
| WO 2014025852 | Feb 2014 | WO |
| WO 2014025854 | Feb 2014 | WO |
| WO 2014026984 | Feb 2014 | WO |
| WO 2014029723 | Feb 2014 | WO |
| WO 2014035140 | Mar 2014 | WO |
| WO 2014039831 | Mar 2014 | WO |
| WO 2014042433 | Mar 2014 | WO |
| WO 2014044691 | Mar 2014 | WO |
| WO 2014047648 | Mar 2014 | WO |
| WO 2014066435 | May 2014 | WO |
| WO 2014066552 | May 2014 | WO |
| WO 2014089379 | Jun 2014 | WO |
| Entry |
|---|
| Abdel-Magid, A., “Inhibitors of ATR Kinase for Treatment on Cancer”, ACS Medicinal Chemistry Letters, 4(8), (2013), pp. 688-689. |
| Ammar, Y.A., et al., “3-Ethoxycarbonylmethylenequinoxalin-2-one in Heterocyclic Synthesis. Part 1: Synthesis of New Substituted and Condensed Quinoxalines”, Afinidad (2005), 62, pp. 151-160. |
| Charrier, J.D., et al, “Discovery of Potent and Selective Inhibitors of Ataxia Telangiesctasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents” J. Med. Chem. (Mar. 17, 2011), 54(7), pp. 2320-2330 (DOI: 10.1021/jm101488z). |
| Charrier, J.D., et al., “Discovery of Potent and Selective Inhibitors of ATR (Ataxia Telangiectasia Mutated and Rad3 Related) as Potential Anticancer Agents”, Supplementary Information, Apr. 14, 2011. |
| Charrier, J.D., “Discovery of potent and selective inhibitors of Ataxia Telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents”, Presentation, ACS Denver 2011, Aug. 28, 2011. |
| Clark, B.A.J., et al., “Mass Spectrometry of Pyrroloä2, 3-Büpyrazines and Pyrazinoä2,3-Büindole”, Organic Mass Spectrometry, 12(7), (1997), pp. 421-423. |
| Curtin, N.J., “Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer”, British Journal of Pharmacology, (2013), pp. 1-52. |
| El-Emary, T.I., “Synthesis and Biological Activity of Some New Pyrazolo[3,4-b]pyrazines”, J. Chin. Chem. Soc. (2006), 53, pp. 391-401. |
| Fernandes, P.S., et al., “Synthesis and Biological Activity of Heterocyclic Derivatives derived from Ethy1-2-hydroxy-quinoxaline-3-carboxylate”, J. Indian Chem. Soc. (1986), 63, pp. 427-429. |
| Finlay, M R. et al. “Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family”, Bioorg. Med. Chem. Letters, 22(17) (2012), pp. 5352-5359. |
| Fokas, E., et al., “Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation”, Cell Death and Disease, 3 (2012), pp. 1-5 (DOI: 10.1038/cddis.2012.181). |
| Fokas, E., et al., “Targeting ATR in DNA damage response and cancer therapeutics”, Cancer Treatment Reviews (2013), (DOI: 10.1016/j.ctrv.2013.03.002). |
| Gentili, F., et al., “Alpha2-Adrenoreceptors Profile Modulation. 4. From Antagonist to Agonist Behavior”, J. Med. Chem., 51(14), Jun. 25, 2008), pp. 4289-4299. |
| Hall-Jackson, C.A., et al., “ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK”, Oncogene, 18(48) (1999), pp. 6707-6713. |
| Hickson, I., et al., “Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM”, Cancer Research (2004), 64, pp. 9152-9159. |
| Hilton, S., et al., “Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2”, Bioorg. Med. Chem., (2010) 18, pp. 707-718. |
| Jiang, B., et al., “Synthesis and cytotoxicity evaluation of novel indolylpyrimidiens and indolylpyrazines as potential antitummor agents”, Bioorganic & Medicinal Chemistry, 9 (2001), pp. 1149-1154. |
| Kim, S.T. et al., “Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members”, J. . Biol. Chem. (1999) 274, pp. 37538-37543. |
| Klicnar, J., et al., “Studien in der Chinoxalinreihe III. Syntheses, Reaktionen and ir-spektren einiger 3-hydroxy-2-carboxymethylch inoxalin-derivative”, Collection Czechoslay. Chem. Commun. (1965), 30, pp. 3092-3101. |
| Kurasawa, Y., et al., “Revised Structure for the Product from the Reaction of 3-Hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline with Nitrous Acid”, Chem. Pharm. Bull. (1984), 32(10), pp. 4140-4143. |
| Luo, H., et al., “Molecular dynamics-based self-organizing molecular field analysis on 3-amino-6-arypyrazines as the ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibitors”, Medicinal Chemistry Research, (2013), pp. 1-12. |
| McKenna, G., et al., “Evaluation of the first potent and highly selective inhibitor of ATR kinase: an approach to selectively sensitize cancer cells to ionizing radiation and hypoxia”, Abstract, Mar. 31, 2012. |
| McKenna, G., et al., “Evaluation of the first potent and highly selective inhibitor of ATR inhibitor, VE-821: an approach to selectively sensitize cancer cells to ionizing radiation and hypoxia”, Poster, Mar. 31, 2012. |
| Middleton, F., et al., “ATR as a Therapeutic Target”, Advances in DNA Repair in Cancer, Northern Institute for Cancer Research, Newcastle University (2013), pp. 211-228. |
| Nakamura, H., et al., “Bimodal chemiluminescence of 8-chlorostyryl-6-phenylethynylimidazopyrazinone: Large bathochromic shift caused by a styryl group at 8-position”, Tetrahedron Letters, 39, (1998), pp. 301-304. |
| Pires, I.M., et al., “Targeting radiation-resisitant hypoxic tumour cells thorugh ATR inhibition”, British Journal of Cancer, Jun. 19, 2012, pp. 1-9. |
| Pollard, J., “Inhibition of the DNA Damage Response Kinase, ATR, as a Promising Anti-Cancer Approach”, Presentation, Mar. 8, 2012. |
| Qi, et al., “Chemi- and bio-luminescence of coelenterazine analogs with phenyl homologs at the C-2 position”, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry,13, (1992), pp. 1607-1611. |
| Reaper, P.M., et al., “Selective Killing of ATM- or p53-deficient cancer cells through inhibition of ATR”, Supplementary Information, Nature Chemical Biology, Apr. 13, 2011, DOI: 10.1038/NCHEMBI0.573. |
| Reaper, P.M., et al., “Selective Killing of ATM- or p53-deficient cancer cells through inhibition of ATR”, Presentation, Nov. 21, 2011. |
| Reaper, P.M., et al., “Selective Killing of ATM- or p53-deficient cancer cells through inhibition of ATR”, Presentation, Nov. 29, 2011. |
| Reaper, P.M., et al., “Evaluation of a potent and highly selective inhibitor of ATR kinase: an approach to selectively sensitize cancer cells to genotoxic drugs”, Abstract, Mar. 31, 2012. |
| Reaper, P.M., et al., “Evaluation of a Potent and Highly Selective Inhibitor of ATR Kinase: An Approach to Selectively Sensitize Cancer Cells to Genotoxic Drugs”, Poster, Mar. 31, 2012. |
| Sarkaria, J.N., et al., “Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine”, Cancer Research (1999) 59, pp. 4375-4382. |
| Sugimoto, T., et al., “Imidazopteridines. I. Synthesis of Imidazo[1,2-c]pteridine and Its Alkyl Derivatives”, Bull. Chem. Soc. Japan (1977) 50(10), pp. 2744-2747. |
| Ward, I.M., et al., “Histone H2AX Is Phosphorylated in an ATR-dependent Manner in Response to Replicational Stress”, J. Biol. Chem. (2001), 51, pp. 47759-47762. |
| Katritzky, A.R., et al., “Efficient synthesis of 3,5-functionalized isoxazoles and isoxazolines via 1,3-dipolar cycloaddition reactions of 1-propargyl- and 1-allylbenzotriazoles”, J. Heterocyclic Chem., 37(6), (2000), pp. 1505-1510. |
| Kumpaty, H.J., et al., “Synthesis of N-Methyl Secondary Amines”, Synth. Commun., 33(8), (2003), pp. 1411-1416. |
| March, J., March's Advanced Organic Chemistry, 2007, John Wiley and Sons, Chapter 16. |
| Saito, R., et al., “Synthesis and in vitro evaluation of botryllazine B analogues as a new class of inhibitor against human aldose reductase”, Tetrahedron, 65 (2009), pp. 3019-3026. |
| Wuts, P.G.M., Greene's Protective Groups in Organic Synthesis, 4th Edition, 2006, John Wiley and Sons, Chapter 4. |
| Wuts, P.G.M., Greene's Protective Groups in Organic Synthesis, 4th Edition, 2006, John Wiley and Sons, Chapter 7. |
| Non-Final Office Action dated Sep. 28, 2013 in U.S. Appl. No. 13/631,727. |
| Non-Final Office Action dated Sep. 28, 2013 in U.S. Appl. No. 13/631,732. |
| Office Communication dated Jun. 27, 2014 for U.S. Appl. No. 14/098,640. |
| International Search Report dated Feb. 6, 2014 in connection with Application No. PCT/US2013/073482. |
| International Search Report and Written Opinion in connection with Application No. PCT/US2012/043897 mailed Jul. 20, 2012. |
| International Search Report and Written Opinion in connection with Application No. PCT/US2012/043896 mailed Nov. 9, 2012. |
| International Search Report and Written Opinion in connection with Application No. PCT/US2012/043895 mailed Aug. 28, 2012. |
| International Search Report and Written Opinion dated Jan. 29, 2014 in connection with Application No. PCT/US2013/073457. |
| International Search Report mailed Jan. 30, 2014 in connection with Application No. PCT/US2013/073477. |
| International Search Report mailed Feb. 17, 2014 in connection with Application No. PCT/US2013/073471. |
| International Search Report and Written Opinion dated Jan. 29, 2015 in connection with Application No. PCT/US2014/068713. |
| International Search Report dated Apr. 1, 2014 in connection with Application No. PCT/US2013/073468. |
| International Search Report and Written Opinion in connection with Application No. PCT/US2011/041705 mailed Aug. 23, 2011. |
| International Search Report for PCT/US2005/040344 mailed Mar. 20, 2006. |
| Ahmed et al., Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines. Eur J Med Chem. Sep. 2009;44(9):3519-23. doi: 10.1016/j.ejmech.2009.03.042. Epub Apr. 8, 2009. |
| Ahmed et al., Synthesis of some Pyrazolopyrimidines as Purine Analogues. J Heterocyclic Chem. 2007;44(4):803-10. |
| Boylan et al., Parenteral Products. Chapter 12. In: Modern Pharmaceuticals. Fourth Edition. 1997:34 pages. |
| Elnagdi et al., Synthesis of Substituted Azaindenes: Synthesis of New Pyrazolo[1,5-a]pyrimidine Derivatives . Bull Chem Soc Jpn. 1990;63(6):1854-56. |
| Ho, Studies on the Synthesis of New 3-(3,5-Diamino-l-substituted-pyrazol-4-yeazo-thieno[2,3-b]pyridines and 3-(2-Amino-5,7-disubstituted-pyrazolo[1,5-a]pyrimidine-3-yeazo-thieno[2,3- b]pyridines. Journal of the Chinese Chemical Society. 1999; 46:955-62. |
| Hubackova et al., Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle. Aug. 1, 2010;9(15):3085-99. doi: 10.4161/cc.9.15.12521. Epub Aug. 26, 2010. |
| Hussein, Novel Synthesis of Some New Pyrimido[1,6-a]pyrimidine and Pyrazolo[1,5-a]pyrimidine Derivatives. J Heterocyclic Chem. 2012;49(2):446-51. |
| Otero et al., Synthesis of Acyclo-C-nucleoside Analogs from 2,3:4,5-Di-Oisopropylidene-D-xylose. J Carbohydrate Chem. 2005;24:809-29. |
| Otero et al., Synthesis of Iso-C-nucleoside Analogues from I-(Methyl 2-0-benzy1-4,6-O-benzylidene-3-deoxy-et-D-altropyranosid-3-yebut-3-yn-2-ones. Z. Naturforsch. 2005; 60b:1175-85. |
| Ram et al., Synthesis of bioisosteric pyrazolo[1,5-a ]pyrimidines as leishmanicides. Indian J Chemistry. 1995;34b:514-20. |
| Reaper et al., Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. Apr. 13, 2011;7(7):428-30. doi: 10.1038/nchembio.573. |
| Ried et al., Synthese newer Heterocyclen ausgehend von Aminopyrazolen. Chemiker•Zeilung. 1989;181-3. |
| Sevilla et al., Microwave-assisted synthesis of 1,3-dihydro-[1,2,5]thiadiazolo[3,4-b]pyrazine2,2-dioxides. Tetrahedron Letters. 2006;47(48):8603-6. |
| Vippagunta et al., Crystalline solids. Adv Drug Deliv Rev. May 16, 2001;48(1):3-26. |
| Wolff, Burger's Medicinal Chemistry and Drug Discovery. Fifth Edition. Volume I: Principles and Practice. 1995;975-7. |
| Number | Date | Country | |
|---|---|---|---|
| 20130034616 A1 | Feb 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61500113 | Jun 2011 | US | |
| 61510200 | Jul 2011 | US | |
| 61620697 | Apr 2012 | US |
